WO2008067928A1

WO2008067928A1 - Uv absorbing compositions containing a pyrrolyltriazine

Info

Publication number: WO2008067928A1
Application number: PCT/EP2007/010247
Authority: WO
Inventors: Carlos Ramon Trullas Cabanas; Oscar Jimenez Alonso; Jordi Corbera Arjona; David Panyella Costa; Olga Gorchs Capa
Original assignee: Isdin SA
Current assignee: Isdin SA
Priority date: 2006-12-04
Filing date: 2007-11-26
Publication date: 2008-06-12
Anticipated expiration: 2009-06-04
Also published as: CL2007003465A1; PE20081198A1; AR064132A1

Abstract

The present invention refers to a combination of at least 2 UV-absorbing active substances (A) and (B), wherein the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (I) which is defined as hereinafter and which has its absorption maximum λmax in the range of UV-A or UV-B radiation, in combination with at least one UV-absorbing active substance (B), which has its absorption maximum λmax(B) in the range of UV-A or UV-B radiation, preferably in such UV radiation range in which the λmax(A) of UV-absorbing active substance (A) does not lie, and wherein the ratio of the molar extinction coefficient at λmax [ελmax(A)] of the UV-absorbing active substance (A) to the molar extinction coefficient at λmax [ελmax(B)] of the UV-absorbing active substance (B) is from 1:10 to 20:1, to a pharmaceutical or a cosmetical composition comprising said combination, to the use of a combination of said active substances for the production of a medicament for the prophylaxis of diseases caused by and/or associated with exposure to ultraviolet radiation and the to use of a combination of active substances for protecting the skin of mammals, as a photostabilizer combination additive or as a component of textile fibers.

Description

Active substance combination

The present invention refers to a combination of at least 2 UV-absorbing active substances (A) and (B)₁ wherein the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (I)

(I)

which is defined as hereinafter and which has its absorption maximum λ_max in the range of UV-A or UV-B radiation, in combination with at least one UV-absorbing active substance (B), which has its absorption maximum λm_ax(B) in the range of UV-A or UV-B radiation, preferably in such UV radiation range in which the λ_max(A) of UV-absorbing active substance (A) does not lie, and wherein the ratio of the molar extinction coefficient at λ_max [ελmax(A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at λ_max [ελ_maX(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , to a pharmaceutical or a cosmetical composition comprising said combination, to the use of a combination of said active substances for the production of a medicament for the prophylaxis of diseases caused by and/or associated with exposure to ultraviolet radiation and the to use of a combination of active substances for protecting the skin of mammals, as a photostabilizer combination additive or as a component of textile fibers.

Ultraviolet (UV) radiation is part of the electromagnetic spectrum emitted by the sun. Whereas UV-C radiation (wavelength [λ] range of 100-290 nm; λ_1Oo-₂₉o) are absorbed by the atmospheric ozone, most radiation in the UV-A range of 320-400 nm (λ₃₂o-4oo) and about 10 % of the UVB radiation range of 290-320 nm (λ₂go-32o) reach the earth's surface. UV-A as well as UV-B radiation is of major importance for human health.

Small amounts of UV radiation are essential for the production of vitamin D in mammals, especially in human beings, yet overexposure may result in acute and chronic health effects of the skin, eye and/or the immune system. To prevent damage of the skin caused by UV-A and UV-B radiation, human beings have developed various natural protection systems either to absorb or to deflect said radiation, like the production of melanin, a fatty layer on the skin, and/or the growth of hair.

In addition, UV-absorbing substances have been developed in order to prevent and/or reduce the effects of solar radiation. Such UV-absorbing substances are compounds that are applied to the skin, lips, nails and/or hair of mammals, especially human beings, in form of additives in cosmetic, dermatological and pharmaceutical formulations. They can also be used as components in polymer compositions, as a component of textile fibers to prevent decomposition of components sensitive to UV radiation or as a further sun protection by means of clothes comprising such fibers.

Despite the great diversity of commercially available sunscreens, there still exists a need for sunscreens, which provide at least a high effectiveness either in the UV-A or the UV-B radiation range, preferably in both ranges, since the sunlight radiation intensity, and in consequence the UV radiation, has been increasing continuously. As a consequence there exists a need for a sufficient protection against such increased UV radiation in order to reduce the risk of suffering of diseases such as skin cancer, polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing and/or chronic actinic dermatitis caused by UV-A and/or UV-B radiation.

Therefore, it was an object of the present invention to provide a new and more effective sun screen system for absorbing preferably at least at a higher level either in the UV-A or UV-B radiation range, preferably in both radiation ranges, so that a remarkable protection against these UV reactions is achieved, especially in order to provide enough care and prophylaxis against diseases caused by or associated with the exposure of skin to UV radiation. This object is solved by the provision of the inventive combination of at least 2 UV- absorbing active substances (A) and (B),

wherein

the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (I)

(I) which is defined hereinafter and which has its absorption maximum λ_max(A) either in the range of UV-A or UV-B radiation,

and which is combined with

at least one UV-absorbing active substance (B), which has its absorption maximum λm_ax_(B) either in the range of UV-A or UV-B radiation, preferably with the proviso that λma_x(B) of active substance (B) does not lie in the same UV radiation range wherein the λ_maX(_A) of active substance (A) lies, wherein the ratio of the molar extinction coefficient at λ_max [ελm_aχ(A)] of the UV-absorbing active substance (A) to the molar extinction coefficient at λ_max [ελm_ax(_B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , preferably from 4:10 to 7:1 ;

with the exception of the combination of 37.5% by weight of 2-(1-benzyl-1 H-pyrrol-2- yl)-4,6-bis(9-oxo-9H-fluoren-3-ylamino)-1 ,3,5-triazine with 62.5% by weight of ethylhexyl methoxycinnamate in each case related to the total weight of both UV- absorbing active substances, with the exception of the combination of 60.5 - 67.6% by weight of 2-(1-benzyl-1 H- pyrrol-2-yl)-4,6-bis[4-(imidazo[1 ,2-a]pyridin-2-yl)phenylamino]-1 ,3,5-triazine with 32.4

- 39.5% by weight of titanium dioxide, in each case related to the total weight of both UV-absorbing active substances,

with the exception of the combination of 8% by weight of 2-(1-benzhydryl-1 H-pyrrol-2- yl)-4,6-bis[4-(butoxycarbonyl)phenylamino]-1 ,3,5-triazine with 60% by weight of ethylhexyl methoxycinnamate and 32% by weight of (2-Hydroxy-4-methoxyphenyl)- phenylmethanone (Benzophenone-3), in each case related to the total weight of all UV-absorbing active substances,

with the exception of the combination of 21 % by weight of 2-(1 -benzyl-1 H-pyrrol-2-yl)- 4,6-bis[4-(butoxycarbonyl)phenylamino]-1 ,3,5-triazine with 79% by weight of ethylhexyl methoxycinnamate, in each case related to the total weight of both UV- absorbing active substances,

with the exception of the combination of 13.4% by weight of 2-(1 -benzyl-1 H-pyrrol-2- yl)-4,6-bis(4-benzoylphenylamino)-1 ,3,5-triazine with 80% by weight of ethylhexyl methoxycinnamate and 6.6% by weight of (2-Hydroxy-4-methoxyphenyl)- phenylmethanone (Benzophenone-3), in each case related to the total weight of all UV-absorbing active substances,

with the exception of the combination of 52.6 - 56.2% by weight of 2-(1 -benzyl-1 H-

benzyl-1 H-pyrrol-2-yl)-1 ,3,5-triazine-2,4-diyl)bis(3-(2-ethylhexyloxy)phenol) with 43.8

- 47.4% by weight of titanium dioxide, in each case related to the total weight of both UV-absorbing active substances,

and

with the exception of the combination of 51.3% by weight of 2-(1 -benzyl-1 H-pyrrol-2- yl)-4,6-bis(biphenyl-4-ylamino)-1 ,3,5-triazine with 30.7% by weight of ethylhexyl methoxycinnamate, 10.3% per weight of (2-Hydroxy-4-methoxyphenyl)- phenylmethanone (Benzophenone-3) and 7.7% by weight of butyl methoxydibenzoylmethane (Avobenzone), in each case related to the total weight of all UV-absorbing active substances.

By means of providing such absorbing inventive combination an improved sun protection system is obtained for either UV-A or UV-B radiation, or, preferably a complementary UV-absorbing system for absorbing UV-A and UV-B radiation to a considerable extent is obtained. Additionally, such inventive combination allows for an effective absorption of UV radiation either in the UV-A, the UV-B or in both UV-A and UV-B radiation ranges at a remarkable absorption level, i.e. it absorbs UV radiation from either 320 to 400nm, 290 to 320 nm or 290 to 400 nm at least in such amount that an adequate protection for the skin is provided.

According to the present invention the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (I)

(I) wherein

n= 0, 1 , 2, 3 or 4, preferably 1 , 2, 3 or 4;

R¹ represents a hydrogen atom; a linear or branched, unsubstituted or at least monosubstituted Ci-₃ alkyl radical; or a R² R³ substituted phenyl- radical; R², R² , R³ and R³, independent of each other, each represents a hydrogen atom; a halogen atom; a hydroxy (-OH) residue; an unsubstituted or at least monosubstituted C-ι-₃ alkyl radical; an unsubstituted or at least monosubstituted -O-Ci-₃ radical; or an unsubstituted or at least monosubstituted aryl radical;

with the condition that if n=0, R² or R³ does not represent an acryl radical,

or

R² and R³ form together with the phenyl ring to which they are attached, an unsubstituted or at least mono-substituted naphthalene ring;

R⁴ and R⁵, independent of each other, each represents a hydrogen atom; an unsubstituted or at least monosubstituted C^ alkyl radical; or an unsubstituted or at least mono-substituted aryl radical;

A¹ represents a radical of general formula (II), (III) or (IV)

A < 2 represents a radical of general formula (II) or (V)

wherein R⁶ represents a hydrogen atom; a linear or branched, unsubstituted or at least monosubstituted Ci-₆ alkyl radical; or a hydroxy (-OH) residue;

R⁷ represents a hydrogen atom; an unsubstituted or at least monosubstituted, saturated or unsaturated, C₃-₆ cycloalkyl radical; an unsubstituted or at least monosubstituted, saturated or unsaturated C_5-Io cycloalkyl radical, which contains 1 , 2 or 3 heteroatom(s) as ring member(s) independently selected from the group consisting of O, N and S; an unsubstituted or at least monosubstituted aryl radical; an unsubstituted or at least monosubstituted C_5-io heteroaryl radical which contains 1 , 2 or 3 heteroatom(s) as ring member(s) independently selected from the group consisting of O, N and S; a -C(=O)-OR¹¹ radical; a -C(=O)-NR¹²R¹³ radical; an unsubstituted or at least monosubstituted -O-Ci.-iβ radical; an unsubstituted or at least monosubstituted -O-phenyl or -O-naphtyl radical; an unsubstituted or at least monosubstituted -COR¹⁴ radical; a linear or branched, saturated or unsaturated, Ci_-1S aliphatic radical, which is unsubstituted or at least mono-substituted with at least one hydroxy (-OH) residue, a SO₃M moiety, a -N(R¹⁵J₃ ⁺ moiety or a radical of general formula (Vl)

(Vl) wherein

m = O or 1 ; p = 0, 1 , 2, 3 or 4;

R¹⁶, R¹⁷, R¹⁸, R¹⁹ and R²⁰, independent of each other, each represents an unsubstituted or at least mono-substituted C_1-6 alkyl radical; an unsubstituted or at least mono-substituted -0-C_1-S radical; an unsubstituted or at least mono-substituted aryl radical; or an -Q-Si(R²¹ )₃ radical; R²¹ represents an unsubstituted or at least mono-substituted Ci_-6 alkyl radical; an -O- Ci-₆ radical; an unsubstituted or at least mono-substituted aryl radical;

R¹¹, R¹² and R¹³, independent of each other, each represents a hydrogen atom; a linear or branched, unsubstituted or at least monosubstituted Ci-i₈ alkyl radical; an unsubstituted or at least mono-substituted C_3-6 cycloalkyl radical;

or

R¹² and R¹³ form together with the bridging nitrogen atom an unsubstituted or at least mono-substituted, saturated 5 to 7-membered cycloaliphatic radical, which contains 1 , 2 or 3 heteroatom(s) as ring member(s) independently selected from the group consisting of O, N and S;

R¹⁴ represents an unsubstituted or at least mono-substituted C-_M8 alkyl radical; or an unsubstituted or at least mono-substituted aryl radical;

R¹⁵ represents an unsubstituted or at least mono-substituted C_MS alkyl radical;

M represents H, Na⁺ or K⁺;

R⁶ and R⁷ form together with the phenyl ring an unsubstituted or at least mono- substituted 9 to 15-membered polycyclic ring system;

or

R⁶ and R¹⁴ form together with the phenyl ring an unsubstituted or at least mono- substituted 9 to 15-membered polycyclic ring system;

R⁸ and R⁹, independent of each other, each represents a hydrogen atom; an unsubstituted or at least monosubstituted -C(=0)-Ci-i₈ radical; a linear or branched, saturated or unsaturated Ci--_I8 aliphatic radical, which is unsubstituted or at least mono-substituted with at least one hydroxy (-OH) residue, a -SO₃M moiety, a -N(R¹⁵)₃ ⁺ moiety or a radical of general formula (Vl) as defined above; R¹⁰ represents a hydrogen atom; or a -SO₃M moiety with M representing H, Na⁺ or K⁺;

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt thereof, or at least one corresponding solvate thereof;

which active substance (A) has its absorption maximum λ_max(A) in the range of either UV-A or UV-B radiation

and

is combined with at least one UV-absorbing active substance (B) as defined above, wherein the ratio of the molar extinction coefficient at λ_max [ελmax (A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at λ_maχ [ελmax (B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , preferably 4:10 to 7:1 ;

whereby the aforementioned exceptions apply.

In a preferred embodiment of the present invention, the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (I) as defined above,

wherein

A¹ and A², independent of each other, each represents a radical of general formula (II) or (V)

wherein R⁶, R⁷, R⁸ and R⁹ have the meaning as defined above;

and

is combined with at least one UV-absorbing active substance (B) as defined above, wherein the ratio of the molar extinction coefficient at λ_max [ελ_maχ(A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at λ_max [ελmax(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , preferably 4:10 to 7:1.

According to a further preferred embodiment of the present invention,

the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (IA)

wherein n = 0, 1 , 2, 3 or 4, preferably 1 , 2, 3 or 4; and

R >1¹, D R2 , D R3 , D R4 , D R5 , D R8 and R^a have the meaning as defined above; and/or is at least one pyrrolyltriazine compound of general formula (IB),

(IB) wherein n = 0, 1 , 2, 3 or 4, preferably 1 , 2, 3 or 4;

and

R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ have the meaning as defined above;

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt and/or at least one corresponding solvate of at least one of the afore mentioned pyrrolyltriazine compounds of general formulae (IA) and (IB);

and

is combined with at least one UV-absorbing active substance (B) as defined above, wherein the ratio of the molar extinction coefficient at λ_max [ελm_aχ(A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at λ_max [ελmax(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , preferably 4:10 to 7:1.

According to a further preferred embodiment of the present invention, the UV- absorbing active substance (A) is at least one pyrrolyltriazine compound of general formulae (I), (IA) or (IB) as defined above,

wherein

A¹ and A², independent of each other, each represents a radical selected from the group consisting of

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or a physiologically acceptable salt thereof and/or a corresponding solvate thereof;

and

is combined with at least one UV-absorbing active substance (B) as defined above, wherein the ratio of the molar extinction coefficient at λ_max [ε_λmaχ(_A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at λ_max [ελmax(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , preferably 4:10 to 7:1. According to a further preferred embodiment of the present invention, the UV- absorbing active substance (A) is at least one pyrrolyltriazine compound of general formulae (I), (IA) or (IB) as defined above,

wherein

R¹ represents a hydrogen atom; a methyl, ethyl, iso-propyl, n-propyl, benzyl or phenyl radical which is unsubstituted or at least mono-substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of F, Cl, Br, I; methyl, ethyl, iso-propyl, n-propyl, iso-butyl, n-butyl, tert-butyl; -0-CH₃, -O-C₂H₅, -0-CH₂-CH₂- CH₃ and phenyl; or a phenyl radical which is in each case substituted with 1 or 2 substituent(s) independently selected from the group consisting of H; methyl, ethyl, iso-propyl, n-propyl and phenyl;

R² and R³, independent of each other, each represents a hydrogen atom; methyl, ethyl, iso-propyl, n-propyl or phenyl;

or

R² and R³ form together with the phenyl ring a naphthalene ring which is unsubstituted or at least mono-substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of F, Cl, Br, I; methyl, ethyl, iso- propyl, n-propyl, iso-butyl, n-butyl, tert-butyl; -O-CH₃, -0-C₂H₅, -0-CH₂-CH₂-CH₃ and phenyl;

R⁴ and R⁵, independent of each other, each represents a hydrogen atom; methyl, ethyl, iso-propyl, n-propyl or phenyl;

R⁶ represents a a hydrogen atom; -OH; methyl, ethyl, iso-propyl, n-propyl or phenyl;

R⁷ represents a a hydrogen atom; -OH; methyl, ethyl, iso-propyl, n-propyl, tert-butyl, n-butyl, iso-butyl, phenyl, benzyl, cyclohexyl, -O-phenyl, biphenyl, -C(=O)-OR¹¹; - C(=O)-NR¹²R¹³; or a radical of general formula (Vl)

(Vl)

wherein

m = O or 1 ; p = 0, 1 , 2, 3 or 4;

R¹⁶, R¹⁷, R¹⁸, R¹⁹ and R²⁰, independent of each other, each represents methyl, ethyl, iso-propyl, n-propyl, butyl; -O-CH₃, -0-C₂H₅, -0-CH₂-CH₂-CH₃; or phenyl;

R¹¹, R¹² and R¹³, independent of each other, each represents methyl, ethyl, iso- propyl, n-propyl, tert-butyl, n-butyl, iso-butyl, pentyl, hexyl or 2-ethylhexyl;

R¹⁴ represents methyl, ethyl, iso-propyl, n-propyl, tert-butyl, n-butyl, iso-butyl; or phenyl;

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt and/or at least one corresponding solvate of at least one of the afore mentioned pyrrolyltriazine compounds of general formulae (I), (IA) and (IB);

and is combined with at least one UV-absorbing active substance (B) as defined above, wherein the ratio of the molar extinction coefficient at λ_maχ [ελmax(A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at λ_max [ελmax(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , preferably 4:10 to 7:1.

Particularly preferred as an active substance (A) is at least one pyrrolyltriazine compound selected from the group consisting of

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4-dihydroxyphenyl)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-1 ,3,5- triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl) phenylamino]-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(biphenyl-4-ylamino)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(4-benzoylphenylamino)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(9-oxo-9H-fluoren-3-ylamino)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(imidazo[1 ,2-a]pyridin-2-yl)phenylamino]- 1 ,3,5-triazine,

- 2-(1 -benzhydryl-1 H-pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl)phenylamino]-1 ,3,5- triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydroindol- 1 -yl)phenylamino]-1 ,3,5-triazine

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-((2-ethylhexyloxy)carbonyl)phenylamino]- 1 ,3,5-triazine

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-1 H-imidazo[1 ,2-a]pyridin-2-yl)phenylamino]- 1 ,3,5-triazine

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(1 H-benzo[d]imidazol-2-yl)phenylamino]- 1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(1 H-pyrazol-1-yl)phenylamino]-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[naphthalen-2-ylamino]-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-((E)-3-ethoxy-3-oxoprop-1 - enyl)phenylamino]-1 ,3,5-triazine and

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(E)-styrylphenylamino]-1 ,3,5-triazine; and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or a physiologically acceptable salt thereof and/or a corresponding solvate thereof;

and

is combined with at least one UV-absorbing active substance (B) as defined above, wherein the ratio of the molar extinction coefficient at λ_max [ε_λmaX(A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at λ_max [ελmax(B)] of the UV-absorbing active substance (B) is from 1:10 to 20:1 , preferably 4:10 to 7:1.

It has been surprisingly found, that an efficient protection against UV-A or UV-B as well as UV-A and UV-B radiation is provided, if the ratio of the molar extinction coefficient at λ_max [ε_λmaχ(A)] of the UV-absorbing active substance (A) to the molar extinction coefficient at λ_max [ε_λma_X(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , more preferably from 4:10 to 7:1 , most preferably from 2:8 to 8:1.

The absorption maximum λ_max according to the present invention is defined as the wavelength, at which an UV-absorbing active substance has its absorption maximum. The relevant wavelength range in which the inventive combination absorbs is preferably in the range of UV-A and/or UV-B radiation, i.e. from 290 to 400 nm. The UV-absorbing active substance (A) should have at least one λ_max(A) in either the UV-A or UV-B range, preferably with the proviso defined above, and regardless of any additional absorption capacity in the UV radiation range, wherein the λ_maX(_A) does not lie.

It is also preferred that the absorption maxima Am_3x(A) and λ_maX(B), respectively, at least differ in 10 nm, more preferably in at least 20 nm and most preferably in at least 40 nm to each other. For example, if the absorption maximum λ_max{A) of UV-absorbing active substance (A) corresponds to 310 nm [λ_maχ_(A)=310 nm], the absorption maximum λ_max(B) of UV-absorbing active substance (B) is preferably < 300 nm [λ_max_(B)<300 nm] or > 320 nm [λ_max(B)>320 nm].

The term "absorption" according to the present invention means any of the following means of reducing the exposure to UV radiation like absorbing, extincting, filtering, scattering, deflecting or reflecting of radiation, since absorption only means the ratio of transmitted radiation to the incident radiation, without determining the mechanism according to which the radiation is reduced.

The molar extinction coefficient (ε) of a substance is usually measured in solution and can be calculated by the following equation (E 1 ),

(E 1 ), wherein "I" means the intensity of radiation transmitted through the sample solution with the dissolved substance, "I₀" is the intensity of radiation transmitted through a reference sample consisting of the same solvent but without such substance, "c" is the molar concentration of the substance in moles/liter, and "I" is the path length through the solution in centimeters (usually 1 cm). Under defined conditions with regard to the solvent, pH and temperature the molar extinction coefficient of a particular compound is a constant at a specified wavelength. Common synonyms for the molar extinction coefficient of a substance are molar absorptivity or molar absorption coefficient.

The molar extinction coefficient ε_λmaχ_(A) of the UV-absorbing active substance (A) according to the present invention defines the molar extinction coefficient at the absorption maximum λ_max of UV-absorbing active substance (A). The molar extinction coefficient ε_λmax(_B) of the UV-absorbing active substance (B) according to the present invention defines the molar extinction coefficient at the absorption maximum λ_max of UV-absorbing active substance (B).

In a preferred embodiment of the present invention, the UV-absorbing active substance (B) has its absorption maximum λ_max(_B) in the range of 290 to 400 nm, with the proviso as defined above, and the UV-absorbing active substance (B) is preferably at least one organic and/or at least one inorganic compound known in the art.

Preferably, the UV-absorbing active substance (B) is at least one compound selected from the group comprising substituted acrylic acid derivatives, allantoin derivatives, aminobenzoic acid derivatives, aminobenzamides derivatives, anthranilic acid derivatives, benzalmalonic acid derivatives, benzimidazole derivatives, benzoic acid derivatives, benzophenone derivatives, benzothiazole derivatives, benzotriazole derivatives, benzoxazole derivatives, camphor derivatives, cinnamic acid derivatives, coumarinic acid derivatives, curcumin derivatives, dianisoylmethane derivatives, dibenzalazine derivatives, dibenzoylmethane derivatives, dioxane derivatives, fungi extract, ferulic acid derivatives, furane derivatives, glutamic acid derivatives, imidazoline derivatives, metal oxides, metal dioxides, nicotinic acid derivatives, nitrobenzamides derivatives, nitrobenzoic acid derivatives, nucleic acid derivatives, p- aminobenzoic acid (PABA) derivatives, plant extracts, propenoate derivatives, pyrimidine derivatives, salicylic acid derivatives, tetrazole derivatives, triazine derivatives, tributamine derivatives, urocanic acid derivatives and vitamin B₆ derivatives;

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt and/or at least one corresponding solvate of the afore mentioned substances;

which UV-absorbing active substance (B) has its absorption maximum λ_maX(B) in the range of 290 to 400 nm, with the proviso as defined above.

As far as the active substance (B) is at least one triazine derivative, this active substance (B) has to be different from a compound, which falls under the definition of compounds of general formulae (I), (IA) and (IB) mentioned before.

The aforementioned active substances (B) are known to those skilled in the art and are either obtainable by standard techniques or are commercially available. The term "derivative", as defined in the present invention, refers to substances in form of their respective free bases, acids, salts, esters and/or ethers.

A further preferred embodiment of the present invention, the combination according to the present invention comprises as UV-absorbing active substance (B) at least one compound of general formula (AA)

(AA)

wherein

T¹ and T², independent of each other, each represents a Ci-β alkyl radical which can be unsubstituted or at least mono-substituted with radicals independently selected from the group consisting of Ci_-4 alkyl, C_5-^ cycloalkyl and aryl;

and/or

at least one compound of general formula (AB)

(AB) wherein

T³ represents a -(CONH)_s-phenyl moiety, in which s is 0 or 1 and the phenyl group is unsubstituted or at least mono-substituted with radicals independently selected from the group consisting of -OH₁ C-_M8 alkyl and -0-Ci_-8 alkyl, or a -C(=O)-OT³ moiety, in which T^3' is a Ci--I₈ alkyl radical;

T⁴ represents a hydrogen atom or a C-M alkyl radical; and

T⁵ represents -OH or a -0-Ci_-4 alkyl radical;

and/or

at least one compound of general formula (AC)

(AC)

wherein

T⁶, T⁷, T⁸ and T⁹, independent of each other, each represents a Ci_-8 alkyl radical or an -O-Ci_-8 alkyl radical;

and/or

at least one compound of general formula (AD)

(AD) wherein

T¹⁰, T¹¹ and T¹², independent of each other, each represents a radical selected from the group consisting of phenyl, -O-phenyl or pyrrolyl, which is unsubstituted or at least mono-substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of -OH, -C-MS alkyl, -O-Ci-is alkyl,

alkyl, C5-8 cycloalkyl, a methylidenecamphor group or a -(CH=CH)_n(CO)-OT¹⁰ , with T¹⁰ being either Ci-i₈ alkyl or cinnamyl, and n is O or 1 ;

and/or

at least one compound of general formula (AE)

wherein

T r14 represents a hydrogen atom or a C-M_S alkyl radical; T¹⁵ represents a Ci_-8 alkyl radical which can be unsubstituted, an at least mono- substituted with a phenyl radical or a radical of general formula (Vl¹)

(Vl¹) wherein

m¹ = O or 1 ;

^ = 0, 1 , 2, 3 0^;

R^16', R^17', R^18', R^19' and R j2*0^u" , independent of each other, each represents an unsubstituted or at least mono-substituted Ci_-6 alkyl radical; an unsubstituted or at least mono-substituted -O-C₁-₆ radical; an unsubstituted or at least mono-substituted aryl radical; or an -O-Si(R²¹ )₃ radical with R^21' representing an unsubstituted or at least mono-substituted Ci_-6 alkyl radical; an -0-Ci_-6 radical; an unsubstituted or at least mono-substituted aryl radical;

T¹⁶ represents a Ci_-8 alkyl radical, which can be unsubstituted or an at least mono- substituted with a phenyl radical;

and/or

at least one compound of general formulae (AF), (AG) and (AH)

(AF)

(AG)

(AH)

wherein

each of the symbols X, independent of each other represents an oxygen or sulfur atom or a group NT¹⁷ , each of the symbols Z, independent of each other represents a nitrogen atom or a CH group, each of the symbols T¹⁷, independent of each other represents an -OH group, a halogen atom, a linear or branched C-i-β alkyl radical optionally containing a silicon atom, or a linear or branched -O-Ci_-8 alkyl radical, each of the numbers r is independent of each other 0, 1 or 2, u represents an integer ranging from 1 to 4 inclusive, y is equal to 0 or 1 , each of the numbers r is independent of each other equal to 0 or 1 , each of the symbols T¹⁷ independently represents a hydrogen atom or a linear or branched C-i-β alkyl radical or benzyl group optionally containing a silicon atom;

A¹ represents a radical of valency u selected from the following group of formulae:

(BA) (BB) (BC) (BD)

(BE) (BF)

(BG) (BH)

(Bl) (BJ) (BK)

(BL) (BM) (BN)

(BO) wherein

each of the symbols T¹⁸, independent of each other represents a halogen atom or a linear or branched Ci_-4 alkyl or -0-Ci_-4 alkyl radical, or -OH; T¹⁹ represents a hydrogen atom or a linear or branched Ci_-4 alkyl radical; W represents a carbon or a nitrogen atom; c = 0, 1 , 2, 3 or 4; d = 0, 1 or 2 and e = 0 or 1 ;

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt and/or at least one corresponding solvate of the afore mentioned compounds of general formulae (AA) to (AH).

In a further preferred embodiment of the present invention the active substance (B) is at least one compound selected from the group comprising 2-ethylhexyl 2-cyano-3,3'- diphenylacrylate, ethyl 2-cyano-3,3'-diphenylacrylate, polymer of N-{(2 and 4)[(2- oxoborn-3-ylidene)methyl]benzyl}acrylamide, methyl 4-aminobenzoate, butyl 4- aminobenzoate, 5-methyl-2-(1-methylethyl)-cyclohexyl 2-aminobenzoate, glyceryl aminobenzoate, 2-ethylhexyl-p-dimethylethyl-aminobenzoate, 4-aminobenzamide, homomethyl-N-acetyl-anthranilic acid, menthyl antrhanilate, 2-(1 H-benzimidazol-2- yl)-4-methoxyphenol, 2,2'-bis(benzimidazole), monosodium salt of 2-2'-bis-(1 ,4- phenylene)1 H-benzimidazole-4,6-disulphonic acid, 2-phenylbenzimidazole-5- sulphonic acid, 5,5^I,6,6'-tetramethyl-2,2'-bis(benzimidazole), 5,5'-dimethyl-2,2'- bis(benzimidazole), 6-methoxy-2,2'-bis(benzimidazole), 1 ,4-phenylenebis(2- benzimidazolyl), 1 ,2-phenylenebis)benzimidazolyl), 1 ,4-phenylenebis(N-2-ethylhexyl- 2-benzimidazolyl), 1 ,4-phenylenebis(N-tri-methylsilylmethyl-2-benzimidazolyl), 2-(1 H- benzimidazol-2-yl)benzothiazole, 2-(1 H-benzimidazol-2-yl)benzoxazole, N₁N'- dimethyl-2,2'-bis(benzimidazole), phenylbenzimidazole-5-sulfonic acid (Ensulizole) and its salts , 2-2'-bis-(1 ,4-phenylene)1 H-benzimidazole-4,6-disulphonic acid, 3- methylbutyl 4-(dimethylamino)benzoate, 3,3,5-trimethylcyclohexyl 2-hydroxybenzoate (Homosalate), ethyl 4-aminobenzoate, 4,4-((6-(((1 ,1- dimethylethyl)amino)carbonyl)phenyl)amino) 1 ,3,5-triazine-2,4-diyl)diimino)bis-,bis- (2-ethyl-hexyl)ester) benzoic acid, 2,4-dihydroxy-benzophenone (Benzophenone-1 ), 2,2'-dihydroxy-4-methoxy-benzophenone (dioxybenzone, Benzophenone-8), 2,2'- dihydroxy-4,4'-dimethoxy-benzophenone, 2,2^l,4,4'-tetrahydroxy-benzophenone₁ 2- hydroxy-4-methoxy-4'-methyl-benzophenone, hydroxymethoxy-benzophenone sulfonic acid, (2-Hydroxy-4-methoxyphenyl)-phenylmethanone (Benzophenone-3), 2- hydroxy-4-methoxy-benzophenone-5-sulfonic acid (Benzophenone-4) and its salts, 4- phenyl-benzophenone, 2-ethylhexyl-4'-phenyl-benzophenone-2-carboxylate, 2- hydroxy-4-n-octoxy-benzophenone, 4-hydroxy-3-carboxy-benzophenone, 2-hydroxy- 4-methoxybenzophenone, 4-(2-β-glucopyranosiloxy)-propoxy-2- hydroxybenzophenone, dihydroxy-dimethoxy-disulfobenzophenone, 2-benzothiazol- 2-ylphenol, [2,4'-dihydroxy-3-(2H-benzotriazol-2-yl)-5-(1 ,1 ,3,3-tetramethylbutyl)-2'-n- octoxy-5'-benzoyl]-diphenylmethane, 2,2'-hydroxy-5-methylphenyl-benzotriazole, 2- (2'-hydroxy-5'-t-octylphenyl)benzotriazole, 2-(2'-hydroxy-5'- methylphenyl)benzotriazole, 2,2'-methylene-bis-6-(2H-benzotriazol-2-yl)-4- (tetramethyl-butyl)-i ,1 ,3,3-phenol, 2-benzoxazole-2-yl-4-methylphenol, 2-phenyl-5- methylbenzoxazole, 1 ,4-phenylenebis(2-benzoxazolyl), 1 ,3-phenylenebis(2- benzoxazolyl), 1 ,2-phenylenebis(2-benzoxazolyl), 2-(2-benzofuryl)-benzoxazole, 2- (benzofuryl)-5-methylbenzoxazole, 2-(3-methyl-2-benzofuryl)benzoxazole, 3-(4'- methylbenzylidene)-D,L-camphor, terephthalylidene dicamphor sulphonic acid, 3- benzylidene-D,L-camphor, 4-benzylidene-D,L-camphor, di-tert-butyl hydroxybenzylidene camphor, benzylidene camphor sulphonic acid, camphor benzalkonium methosulfate, polyacrylamido-methyl benzylidene camphor, ethylhexyl methoxycinnamate, diethanolamine p-methoxy cinnamate, isopropyl-p-acetamido cinnamate, octyl cinnamate, ethyl-4-isopropylcinnamate, methyl-2,5-diisopropyl cinnamate, ethyl-2,4-diisopropylcinnamate, methyl-2,4-diisopropylcinnamate, propyl- p-methoxycinnamate, isopropyl-p-methoxycinnamate, diisopropylcinnamate esters, isoamyl-p-methoxycinnamate, cyclohexyl-p-methoxycinnamate, ethyl-α-cyano-β- phenylcinnamate, 2-ethylhexyl-α-cyano-β-phenylcinnamate, glycerin-mono-2-ethyl- hexanoyl-diparamethoxycinnamate, glyceryl octanoate-di-p-methoxycinnamate, DEA- methoxycinnamate, methyl-bis(trimethyl-siloxy)silyl-isopentyl-trimethoxycinnamate, ethyl-α-cyano-3,5-dimethoxy-4-hydroxy cinnamate, ethyl-α-acetyl-3,5-dimethoxy-4- hydroxy cinnamate, iso-propyl-α-acetyl-3,5-dimethoxy-4-hydroxy cinnamate, iso- amyl-α-acetyl-3,5-dimethoxy-4-hydroxy cinnamate, 2-ethylhexyl-α-acetyl-3,5- dimethoxy-4-hydroxy cinnamate, ethyl-α-cyano-3-methoxy-4-hydroxy cinnamate, ethyl-α-acetyl-3-methoxy-4-hydroxy cinnamate, iso-propyl-α-acetyl-S-methoxy^- hydroxy cinnamate, iso-amyl-α-acetyl-S-methoxy^-hydroxy cinnamate, 2-ethylhexyl- α-acetyl-3-methoxy-4-hydroxy cinnamate, 7-ethylamino-4-methylcoumarin, 7,8- dihydroxycoumarin, 6,7-dihydroxycoumarin, 7-hydroxycoumarin, 4-methyl-7- hydroxycoumarin, diacetylcurcumin, tetrahydrocurcumin diacetate, dianisoylmethane, dibenzalazine, butyl methoxydibenzoylmethane (Avobenzone), 2- methyldibenzoylmethane, 4-methyldibenzoylmethane, 4-isopropyldibenzoylmethane, 4-tert-butyldibenzoylmethane, 2,4-dimethyldibenzoylmethane, 2,5- dimethyldibenzoylmethane, 4,4'-diisopropyldibenzoylmethane, 4,4'- dimethoxydibenzoylmethane, 2-methyl-5-isopropyl-4^I-methoxydibenzoylmethane, 2- methyl-5-tert-butyl-4'-methoxydibenzoylmethane, 2,4-dimethyl-4'- methoxydibenzoylmethane, 2,6-dimethyl-4-tert-butyl-4^l-methoxydibenzoylmethane, ferulic acid, dimethicodiethylbenzalmalonate, diethyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, di-(2-ethylhexyl)-3,5-dimethoxy-4-hydroxy benzylidene malonate, diisoamyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, didodecyl-3,5- dimethoxy-4 hydroxy benzylidene malonate, dipalmitoyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, di-isopropyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, diethyl-3-methoxy-4-hydroxy benzylidene malonate, di-(2-ethylhexyl)-3-methoxy-4- hydroxy benzylidene malonate, diisoamyl-3-methoxy-4-hydroxy benzylidene malonate, didodecyl-3-methoxy-4-hydroxy benzylidene malonate, dipalmitoyl-3- methoxy-4-hydroxy benzylidene malonate, di-isopropyl-3-methoxy-4-hydroxy benzylidene malonate, hydrolyzed aspergillus sp. extract ferment, calcium cerium oxide, cerium oxide, iron oxide, manganese oxide, titanium dioxide, zinc oxide, zinc cerium oxide, zirconium oxide, 4-nitrobenzamide, 4-nitrobenzoic acid, p- aminobenzoic acid (PABA), PABA-monoglycerinester, N,N-dipropoxy-PABA- ethylester, N,N-diethoxy PABA-ethylester, N,N-dimethyl PABA-ethylester, N₁N- dimethyl PABA-butylester, PEG-25 PABA, N,N-dimethyl PABA-amylester, N, N- dimethyl PABA-octlylester (2-ethylhexyl 4-(dimethylamino)benzoate, Padimate O), octyl dimethyl PABA, ethyl-dihydroxypropyl-PABA, isoamyl dimethyl PABA (3- methylbutyl 4-(dimethylamino)benzoate, Padimate A), 1-(3,4-dimethoxyphenyl)-4,4- diemthyl-1 ,3-pentanedione, 5-(3,3-Dimethyl-2-norbornyliden)-3-pentane-2-one, 1-(4- methoxyphenyl)-3-(4-tert-butylphenyl)propane-1 ,3-dione, dipropylene glycol salicylate, 2-ethylhexyl 2-cyano-3,3-diphenyl-2-propenoate (Octocrylene), hydrolyzed soy extract, hydrolyzed linseed extract, sunflower seed extract, grape seed extract, pinus pinaster bark extract, pinus pinaster bud extract, ginseng extract ferment, spirulina platensis powder, phenyl salicylate, p-tert-butylphenyl salicylate, p- octylphenyl salicylate, 2-ethylhexyl salicylate (octyl salicylate), amyl salicylate, menthyl salicylate, homomenthyl salicylate, benzyl salicylate, p-isopropanol-phenyl salicylate, TEA-salicylate, 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1 ,3,3,3- tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol (Mexoryl XL), 2-[p-(tert- butylamido)anilino]-4,6-bis[p-(2'-ethylhexyl-1 '-oxycarbonyl)anilino]-1 ,3,5-triazine (INCI name: Diethylhexyl Butamido Triazone), 2,4,6-tris[4-(2-ethylhexyl-oxycarbonyl)- anilino]-1 ,3,5-triazine (INCI name: Ethylhexyl Triazone), (1 ,3,5)-triazine-2,4-bis((4-2- ethyl-hexyloxy)-2-hydroxy)-phenyl)-6-(4-methoxy-phenyl) (bemotrizinol), octyl triazone (CAS-no.: 88122-99-0), urocanic acid, ethyl-urocanic acid, talc, kaolin, calcium carbonate, , bisoctrizole (CAS-no.: 103597-45-1), bomelone (CAS-no.: 2226- 11-1 ), 2-Hydroxy-1 ,4-naphthochinone (Lawsone, CAS-no.: 83-72-7), petrolatum red, phenol sulphonate, sodium 3,4-dimethylphenyl-glyoxylate, 3,3'-(1 ,4- phenylenedimethylene-bis-(7,7-dimethyl-2-oxobicyclo-[2,2,1]hept-1-yl- methanesufonic acid, α-(2-oxoborn-3-ylidene)-toluene-4-sulphonic acid, 2-(2H- benzotriazole-2-yl)-4-methyl-6-[2-methyl-3-[1 ,3,3,3-tetramethyl-1- [(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol (INCI name: drometrizole trisiloxane, DTS), digalloyl trioleate, dimethicone/PEG-15 crosspolymer, ethylhexyl-bis-isopentyl- benzoxazolyl-phenyl melamine and 2-ethylhexyl-dimethoxy-benzylidene-dioxo- imidazolidine propionate;

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt and/or at least one corresponding solvate of the afore mentioned compounds;

and/or

a compound of general formula (X)

wherein

R^1x represents a hydrogen atom; an optionally substituted cycloalkyl radical from 3 to 7 carbon atoms; an aryl radical which is unsubstituted or at least mono-substituted with a group selected from aryl, halogen, an -0-Ci_-6 radical and a Ci_-6 alkyl radical; a -phenyl-C_1-6 alkyl radical; a linear or branched Ci_-8 alkyl radical which is unsubstituted or at least mono-substituted with a moiety selected from -SO₃M, -N(R^4x)₃ ⁺ and a radical of general formula (XX)

(XX) wherein

y = 0 or 1 ; z = 0, 1 , 2, 3 or 4;

R^5x, R^6x, R^7x, R^8x and R^9x, independent of each other, each represents an unsubstituted or at least mono-substituted Ci-₆ alkyl radical; an -O-C₁-₆ radical; an unsubstituted or at least mono-substituted aryl radical and an -OSi(R^10x)₃ radical; R^1Ox represents a Ci-₆ alkyl radical; an -0-C_1-6 radical; or an unsubstituted or at least mono-substituted aryl radical;

M represents a hydrogen atom, Na⁺ or K⁺;

R^4x represents an unsubstituted or at least mono-substituted Ci_-6 alkyl radical;

R^2x and R^3x, independent of each other, each represents a hydrogen atom; an unsubstituted or at least monosubstituted Ci_₄ alkyl radical; or an unsubstituted or at least mono-substituted aryl radical;

A , 1x represents a radical of general formula (X1 ) or (X2)

A ι 2x represents a radical of general formula (X1 ), (X3) or (X4)

R^11x represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted Ci_-6 aliphatic radical; or a hydroxy (-OH) residue;

R^12x represents a hydrogen atom; a -C(=O)-OR^15x radical; a -C(=O)-NR^16xR^17x radical; an unsubstituted or at least monosubstituted -0-CM₈ radical; an unsubstituted or at least monosubstituted -O-phenyl radical; a C_5-7 cycloalkyl radical; a phenyl or a naphtyl radical; a phenyl or a naphtyl radical which are substituted by 1 or 2 substituents which are independently from one another selected from the group consisting of phenyl, Cl, -0-Ci_-6 alkyl and Ci_-6 alkyl; a linear or branched, saturated or unsaturated CMB aliphatic radical which is unsubstituted or at least mono-substituted with -OH, -phenyl or un moiety of general formula (XX) as defined above;

pⁱsx R^16χ _ancj p^i7χ j_nc|_ependent of each other, each represents a hydrogen atom; a linear or branched, unsubstituted or at least mono-substituted C-i.-iβ alkyl radical;

R^14x represents hydrogen atom; or -SO₃M, with M being H, Na⁺ or K⁺;

R^13x and R^l13x, independent of each other, each represents a hydrogen atom; an unsubstituted or at least monosubstituted

radical; a linear or branched C₁-₁₈ alkyl radical, which is unsubstituted or at least mono-substituted with at least one hydroxy (-OH) residue, a SO₃M moiety, a -N(R^4x)₃ ⁺ moiety, wherein M and R^4x have the meaning as defined above, or a radical of general formula (XX) as defined above;

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt and/or at least one corresponding solvate of the afore mentioned compounds of general formula (X).

The compounds of general formula (X) can be prepared according to WO 2006/064366, which relevant disclosure is herewith introduced by reference and shall form part of the description.

According to a further preferred embodiment of the present invention the UV- absorbing active substance (A) is at least one pyrrolyltriazine compound selected from the group consisting of

- 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4-dihydroxyphenyl)-1 ,3,5-triazine, - 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-1 ,3,5- triazine,

- 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl) phenylamino]-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(biphenyl-4-ylamino)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(4-benzoylphenylamino)-1 , 3, 5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydroindol- 1 -yl)phenylamino]-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-((2-ethylhexyloxy)carbonyl)phenylamino]- 1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-1 H-imidazo[1 ,2-a]pyridin-2-yl)phenylamino]- 1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(1 H-pyrazol-1 -yl)phenylamino]-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[naphthalen-2-ylamino]-1 ,3,5-triazine,

- 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-((E)-3-ethoxy-3-oxoprop-1 - enyl)phenylamino]-1 ,3,5-triazine and

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(E)-styrylphenylamino]-1 ,3,5-triazine;

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt and/or at least one corresponding solvate thereof;

which is combined with

at least one inorganic UV-absorbing active substance (B) selected from the group comprising cerium oxide, iron oxide, manganese oxide, titanium dioxide, zinc oxide, zinc cerium oxide and zirconium oxide; and/or

at least one UV-absorbing active substance (B) selected from the group consisting of

- 2, 4-bis(2, 4-dihydroxyphenyl)-6-(1 -methyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine,

- 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(1 -methyl-1 H-pyrazol-5-yl)- 1 ,3,5-triazine,

- 2-[2, 4-bis (2-ethylhexyloxy)phenyl]-4-[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-6- (1 -methyl-1 H-pyrazol-5-yl)-1 ,3,5- triazine,

- 2,4-bis(2, 4-dihydroxyphenyl)-6(1-phenyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine,

- 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(1 -phenyl-1 H-pyrazol-5-yl)- 1 ,3,5-triazine,

- 2,4-bis [4-(butoxycarbonyl)phenylamino]-6-(1 -methyl-1 H-pyrazol-5-yl)-1 ,3,5- triazine,

- 2, 4-bis{4-[(2-(ethylhexyloxy)carbonyl]phenylamino}-6-(1 -methyl-1 H-pyrazol-5- yl)-1 ,3,5-triazine,

- 2,4-bis [4-(butoxycarbonyl)phenylamino]-6-(1 -phenyl-1 H-pyrazol-5-yl)-1 ,3,5- triazine,

- 2,4-bis{4-[(2-ethylhexyloxy)carbonyl]phenylamino}-6-( 1 -phenyl-1 H-pyrazol-5-yl)- 1 ,3,5-triazine,

- 2-[(4-butoxycarbonyl)phenylamino]-4,6-bis(1 -methyl-1 H-pyrazol-5-yl)-1 ,3,5- triazine;

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt and/or at least one corresponding solvate thereof.

According to a further preferred embodiment of the present invention the UV- absorbing active substance (A) is at least one pyrrolyltriazine compound selected from the group consisting of - 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4-dihydroxyphenyl)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl)phenylamino]-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(biphenyl-4-ylamino)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(4-benzoylphenylamino)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[naphthalen-2-ylamino]-1 ,3,5-triazine,

2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(E)-styrylphenylamino]-1 ,3,5-triazine;

which is combined with at least one inorganic UV-absorbing active substance (B) selected from the group comprising cerium oxide, iron oxide, manganese oxide, titanium dioxide, zinc oxide, zinc cerium oxide, zirconium oxide;

and/or

at least one compound selected from the group comprising 2, 4-bis(2, 4- dihydroxyphenyl)-6-(1-methyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine, 2,4-bis{[4-(2- ethylhexyloxy)-2-hydroxy]phenyl}-6-(1 -methyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine, 2-[2, 4- bis (2-ethylhexyloxy)phenyl]-4-[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-6-(1-methyl-1 H- pyrazol-5-yl)-1 ,3,5- triazine, 2,4-bis(2, 4-dihydroxyphenyl)-6(1-phenyl-1 H-pyrazol-5- yl)-1 ,3,5-triazine, 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(1 -phenyl-1 H- pyrazol-5-yl)-1 ,3,5-triazine, 2,4-bis [4-(butoxycarbonyl)phenylamino]-6-(1 -methyl-1 H- pyrazol-5-yl)-1 ,3,5-triazine, 2,4-bis{4-[(2-(ethylhexyloxy)carbonyl]phenylamino}-6-(1- methyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine, 2,4-bis [4-(butoxycarbonyl)phenylamino]-6-(1- phenyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine, 2,4-bis{4-[(2- ethylhexyloxy)carbonyl]phenylamino}-6-(1 -phenyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine and 2-[(4-butoxycarbonyl)phenylamino]-4,6-bis(1 -methyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine,

and

A particularly preferred embodiment of the present invention is a combination of the UV-absorbing active substance (A)

2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4-dihydroxyphenyl)-1 ,3,5-triazine with the formula

which is combined with

at least one UV-absorbing active substance (B) selected from the group consisting of 2-ethylhexyl 2-cyano-3,3'-diphenylacrylate, ethyl 2-cyano-3,3'-diphenylacrylate, polymer of N-{(2 and 4)[(2-oxoborn-3-ylidene)methyl]benzyl}acrylamide, methyl A- aminobenzoate, butyl 4-aminobenzoate, 5-methyl-2-(1-methylethyl)-cyclohexyl 2- aminobenzoate, glyceryl aminobenzoate, 2-ethylhexyl-p-dimethylethyl- aminobenzoate, 4-aminobenzamide, homomethyl-N-acetyl-anthranilic acid, menthyl antrhanilate, 2-(1 H-benzimidazol-2-yl)-4-methoxyphenol, 2,2'-bis(benzimidazole), monosodium salt of 2-2'-bis-(1 ,4-phenylene)1 H-benzimidazole-4,6-disulphonic acid, 2-phenylbenzimidazole-5-sulphonic acid, δ.δ'.β.β'-tetramethyl^^'- bis(benzimidazole), 5,5'-dimethyl-2,2'-bis(benzimidazole), δ-methoxy-2,2¹- bis(benzimidazole), 1 ,4-phenylenebis(2-benzimidazolyl), 1 ,2- phenylenebis)benzimidazolyl), 1 ,4-phenylenebis(N-2-ethylhexyl-2-benzimidazolyl), 1 ,4-phenylenebis(N-tri-methylsilylmethyl-2-benzimidazolyl), 2-(1 H-benzimidazol-2- yl)benzothiazole, 2-(1 H-benzimidazol-2-yl)benzoxazole, N,N'-dimethyl-2,2'- bis(benzimidazole), phenylbenzimidazole-5-sulfonic acid (Ensulizole) and its salts , 2- 2'-bis-(1 ,4-phenylene)1 H-benzimidazole-4,6-disulphonic acid, 3-methylbutyl A- (dimethylamino)benzoate, 3,3,5-trimethylcyclohexyl 2-hydroxybenzoate (Homosalate), ethyl 4-aminobenzoate, 4,4-((6-(((1 ,1- dimethylethyl)amino)carbonyl)phenyl)amino) 1 ,3,5-triazine-2,4-diyl)diimino)bis-,bis- (2-ethyl-hexyl)ester) benzoic acid, 2,4-dihydroxy-benzophenone (Benzophenone-1 ), 2,2'-dihydroxy-4-methoxy-benzophenone (dioxybenzone, Benzophenone-8), 2,2'- dihydroxy-4,4'-dimethoxy-benzophenone, 2,2¹,4,4'-tetrahydroxy-benzophenone, 2- hydroxy-4-methoxy-4'-methyl-benzophenone, hydroxymethoxy-benzophenone sulfonic acid, (2-Hydroxy-4-methoxyphenyl)-phenylmethanone (Benzophenone-3), 2- hydroxy-4-methoxy-benzophenone-5-sulfonic acid (Benzophenone-4) and its salts, A- phenyl-benzophenone, 2-ethylhexyl-4'-phenyl-benzophenone-2-carboxylate, 2- hydroxy-4-n-octoxy-benzophenone, 4-hydroxy-3-carboxy-benzophenone, 2-hydroxy- 4-methoxybenzophenone, 4-(2-β-glucopyranosiloxy)-propoxy-2- hydroxybenzophenone, dihydroxy-dimethoxy-disulfobenzophenone, 2-benzothiazol- 2-ylphenol, [2,4'-dihydroxy-3-(2H-benzotriazol-2-yl)-5-(1 ,1 ,3,3-tetramethylbutyl)-2'-n- octoxy-5'-benzoyl]-diphenylmethane, 2,2^I-hydroxy-5-methylphenyl-benzotriazole, 2- (2'-hydroxy-5'-t-octylphenyl)benzotriazole, 2-(2'-hydroxy-5'- methylphenyl)benzotriazole, 2,2¹-methylene-bis-6-(2H-benzotriazol-2-yl)-4- (tetramethyl-butyl)-i ,1 ,3,3-phenol, 2-benzoxazole-2-yl-4-methylphenol, 2-phenyl-5- methylbenzoxazole, 1 ,4-phenylenebis(2-benzoxazolyl), 1 ,3-phenylenebis(2- benzoxazolyl), 1 ,2-phenylenebis(2-benzoxazolyl), 2-(2-benzofuryl)-benzoxazole, 2- (benzofuryl)-5-methylbenzoxazole, 2-(3-methyl-2-benzofuryl)benzoxazole, 3-(4'- methylbenzylidene)-D,L-camphor, terephthalylidene dicamphor sulphonic acid, 3- benzylidene-D,L-camphor, 4-benzylidene-D,L-camphor, di-tert-butyl hydroxybenzylidene camphor, benzylidene camphor sulphonic acid, camphor benzalkonium methosulfate, polyacrylamido-methyl benzylidene camphor, ethylhexyl methoxycinnamate, diethanolamine p-methoxy cinnamate, isopropyl-p-acetamido cinnamate, octyl cinnamate, ethyl-4-isopropylcinnamate, methyl-2,5-diisopropyl cinnamate, ethyl-2,4-diisopropylcinnamate, methyl-2,4-diisopropylcinnamate, propyl- p-methoxycinnamate, isopropyl-p-methoxycinnamate, diisopropylcinnamate esters, isoamyl-p-methoxycinnamate, cyclohexyl-p-methoxycinnamate, ethyl-α-cyano-β- phenylcinnamate, 2-ethylhexyl-α-cyano-β-phenylcinnamate, glycerin-mono-2-ethyl- hexanoyl-diparamethoxycinnamate, glyceryl octanoate-di-p-methoxycinnamate, DEA- methoxycinnamate, methyl-bis(trimethyl-siloxy)silyl-isopentyl-trimethoxycinnamate, ethyl-α-cyano-3 , 5-d imethoxy-4-hyd roxy ci n namate , ethyl-α-acetyl-3 , 5-d imethoxy-4- hydroxy cinnamate, iso-propyl-α-acetyl-3,5-dimethoxy-4-hydroxy cinnamate, iso- amyl-α-acetyl-3,5-dimethoxy-4-hydroxy cinnamate, 2-ethylhexyl-α-acetyl-3,5- dimethoxy-4-hydroxy cinnamate, ethyl-α-cyano-3-methoxy-4-hydroxy cinnamate, ethyl-α-acetyl-3-methoxy-4-hydroxy cinnamate, iso-propyl-α-acetyl-3-methoxy-4- hydroxy cinnamate, iso-amyl-α-acetyl-3-methoxy-4-hydroxy cinnamate, 2-ethylhexyl- α-acetyl-3-methoxy-4-hydroxy cinnamate, 7-ethylamino-4-methylcoumarin, 7,8- dihydroxycoumarin, 6,7-dihydroxycoumarin, 7-hydroxycoumarin, 4-methyl-7- hydroxycoumarin, diacetylcurcumin, tetrahydrocurcumin diacetate, dianisoylmethane, dibenzalazine, butyl methoxydibenzoylmethane (Avobenzone), 2- methyldibenzoylmethane, 4-methyldibenzoylmethane, 4-isopropyldibenzoylmethane, 4-tert-butyldibenzoylmethane, 2,4-dimethyldibenzoylmethane, 2,5- dimethyldibenzoylmethane, 4,4'-diisopropyldibenzoylmethane, 4,4'- dimethoxydibenzoylmethane, 2-methyl-5-isopropyl-4'-methoxydibenzoylmethane, 2- methyl-5-tert-butyl-4'-methoxydibenzoylmethane, 2,4-dimethyl-4'- methoxydibenzoylmethane, 2,6-dimethyl-4-tert-butyl-4'-methoxydibenzoylmethane₁ ferulic acid, dimethicodiethylbenzalmalonate, diethyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, di-(2-ethylhexyl)-3,5-dimethoxy-4-hydroxy benzylidene malonate, diisoamyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, didodecyl-3,5- dimethoxy-4 hydroxy benzylidene malonate, dipalmitoyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, di-isopropyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, diethyl-3-methoxy-4-hydroxy benzylidene malonate, di-(2-ethylhexyl)-3-methoxy-4- hydroxy benzylidene malonate, diisoamyl-3-methoxy-4-hydroxy benzylidene malonate, didodecyl-3-methoxy-4-hydroxy benzylidene malonate, dipalmitoyl-3- methoxy-4-hydroxy benzylidene malonate, di-isopropyl-3-methoxy-4-hydroxy benzylidene malonate, hydrolyzed aspergillus sp. extract ferment, calcium cerium oxide, cerium oxide, iron oxide, manganese oxide, titanium dioxide, zinc oxide, zinc cerium oxide, zirconium oxide, 4-nitrobenzamide, 4-nitrobenzoic acid, p- aminobenzoic acid (PABA), PABA-monoglycerinester, N,N-dipropoxy-PABA- ethylester, N,N-diethoxy PABA-ethylester, N,N-dimethyl PABA-ethylester, N, N- dimethyl PABA-butylester, PEG-25 PABA, N,N-dimethyl PABA-amylester, N, N- dimethyl PABA-octlylester (2-ethylhexyl 4-(dimethylamino)benzoate, Padimate O), octyl dimethyl PABA, ethyl-dihydroxypropyl-PABA, isoamyl dimethyl PABA (3- methylbutyl 4-(dimethylamino)benzoate, Padimate A), 1-(3,4-dimethoxyphenyl)-4,4- diemthyl-1 ,3-pentanedione, 5-(3,3-Dimethyl-2-norbomyliden)-3-pentane-2-one, 1-(4- methoxyphenyl)-3-(4-tert-butylphenyl)propane-1 ,3-dione, dipropylene glycol salicylate, 2-ethylhexyl 2-cyano-3,3-diphenyl-2-propenoate (Octocrylene), hydrolyzed soy extract, hydrolyzed linseed extract, sunflower seed extract, grape seed extract, pinus pinaster bark extract, pinus pinaster bud extract, ginseng extract ferment, spirulina platensis powder, phenyl salicylate, p-tert-butylphenyl salicylate, p- octylphenyl salicylate, 2-ethylhexyl salicylate (octyl salicylate), amyl salicylate, menthyl salicylate, homomenthyl salicylate, benzyl salicylate, p-isopropanol-phenyl salicylate, TEA-salicylate, 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1 ,3,3,3- tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol (Mexoryl XL), 2-[p-(tert- butylamido)anilino]-4,6-bis[p-(2'-ethylhexyl-1 '-oxycarbonyl)anilino]-1 ,3,5-triazine (INCI name: Diethylhexyl Butamido Triazone), 2,4,6-tris[4-(2-ethylhexyl-oxycarbonyl)- anilino]-1 ,3,5-triazine (INCI name: Ethylhexyl Triazone), (1 ,3,5)-triazine-2,4-bis((4-2- ethyl-hexyloxy)-2-hydroxy)-phenyl)-6-(4-methoxy-phenyl) (bemotrizinol), octyl triazone (CAS-no.: 88122-99-0), urocanic acid, ethyl-urocanic acid, talc, kaolin, calcium carbonate, , bisoctrizole (CAS-no.: 103597-45-1), bornelone (CAS-no.: 2226- 11-1 ), 2-Hydroxy-1 ,4-naphthochinone (Lawsone, CAS-no.: 83-72-7), petrolatum red, phenol sulphonate, sodium 3,4-dimethylphenyl-glyoxylate, 3,3'-(1.4- phenylenedimethylene-bis-^J-dimethyl^-oxobicyclo-l^.ilhept-i-yl- methanesufonic acid, α-(2-oxoborn-3-ylidene)-toluene-4-sulphonic acid, 2-(2H- benzotriazole-2-yl)-4-methyl-6-[2-methyl-3-[1 ,3,3,3-tetramethyl-1- [(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol (INCI name: drometrizole trisiloxane, DTS), digalloyl trioleate, dimethicone/PEG-15 crosspolymer, ethylhexyl-bis-isopentyl- benzoxazolyl-phenyl melamine and 2-ethylhexyl-dimethoxy-benzylidene-dioxo- imidazolidine propionate, 2, 4-bis(2, 4-dihydroxyphenyl)-6-(1-methyl-1H-pyrazol-5-yl)- 1 ,3,5-triazine, 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(1-methyl-1 H-pyrazol- 5-yl)-1 ,3,5-triazine, 2-[2, 4-bis (2-ethylhexyloxy)phenyl]-4-[4-(2-ethylhexyloxy)-2- hydroxyphenyl]-6-(1-methyl-1 H-pyrazol-5-yl)-1 ,3,5- triazine, 2,4-bis(2, 4- dihydroxyphenyl)-6(1-phenyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine, 2,4-bis{[4-(2- ethylhexyloxy)-2-hydroxy]phenyl}-6-(1-phenyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine, 2,4-bis [4-(butoxycarbonyl)phenylamino]-6-(1-methyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine, 2,4- bis{4-[(2-(ethylhexyloxy)carbonyl]phenylamino}-6-(1-methyl-1 H-pyrazol-5-yl)-1 ,3,5- triazine, 2,4-bis [4-(butoxycarbonyl)phenylamino]-6-(1-phenyl-1 H-pyrazol-5-yl)-1 ,3,5- triazine, 2,4-bis{4-[(2-ethylhexyloxy)carbonyl]phenylamino}-6-(1 -phenyl-1 H-pyrazol-5- yl)-1 ,3,5-triazine and 2-[(4-butoxycarbonyl)phenylamino]-4,6-bis(1-methyl-1 H-pyrazol- 5-yl)-1 ,3,5-triazine;

Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)

2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-1 ,3,5- triazine with the formula

with

at least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine;

with the exception of the combination of 52.6 - 56.2% by weight of 2-(1-benzyl-1 H- pyrrol-2-yl)-4,6-bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-1 ,3,5-triazine/6,6'-(6-(1- benzyl-1 H-pyrrol-2-yl)-1 ,3,5-triazine-2,4-diyl)bis(3-(2-ethylhexyloxy)phenol) with 43.8 - 47.4% by weight of titanium dioxide, in each case related to the total weight of both UV-absorbing active substances.

Another preferred embodiment of the present invention is a combination of UV- absorbing active substance (A)

2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl) phenylamino]-1 ,3,5-triazine with the formula

with at least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine;

and

with the exception of the combination of 21 % by weight of 2-(1-benzyl-1 H-pyrrol-2-yl)- 4,6-bis[4-(butoxycarbonyl)phenylamino]-1 ,3,5-triazine with 79% by weight of ethylhexyl methoxycinnamate, in each case related to the total weight of both UV- absorbing active substances.

2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(biphenyl-4-ylamino)-1 ,3,5-triazine with the formula

with

with the exception of the combination of 51.3% by weight of 2-(1-benzyl-1 H-pyrrol-2- yl)-4,6-bis(biphenyl-4-ylamino)-1 ,3,5-triazine with 30.7% by weight of ethylhexyl methoxycinnamate, 10.3% per weight of (2-Hydroxy-4-methoxyphenyl)- phenylmethanone (Benzophenone-3) and 7.7% by weight of butyl methoxydibenzoylmethane (Avobenzone), in each case related to the total weight of all UV-absorbing active substances. Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)

2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(4-benzoylphenylamino)-1 ,3,5-triazine with the formula

with

with the exception of the combination of 13.4% by weight of 2-(1-benzyl-1 H-pyrrol-2- yl)-4,6-bis(4-benzoylphenylamino)-1 ,3,5-triazine with 80% by weight of ethylhexyl methoxycinnamate and 6.6% by weight of (2-Hydroxy-4-methoxyphenyl)- phenylmethanone (Benzophenone-3), in each case related to the total weight of all UV-absorbing active substances.

2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(9-oxo-9H-fluoren-3-ylamino)-1 ,3,5-triazine with the formula

with

at least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine:

with the exception of the combination of 37.5% by weight of 2-(1 -benzyl-1 H-pyrrol-2- yl)-4,6-bis(9-oxo-9H-fluoren-3-ylamino)-1 ,3,5-triazine with 62.5% by weight of ethylhexyl methoxycinnamate in each case related to the total weight of both UV- absorbing active substances.

2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(imidazo[1 ,2-a]pyridin-2-yl)phenylamino]-1 ,3,5- triazine with the formula

with

at least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine; with the exception of the combination of 60.5 - 67.6% by weight of 2-(1-benzyl-1 H- pyrrol-2-yl)-4,6-bis[4-(imidazo[1 ,2-a]pyridin-2-yl)phenylamino]-1 ,3,5-triazine with 32.4 - 39.5% by weight of titanium dioxide, in each case related to the total weight of both UV-absorbing active substances.

2-(1-benzhydryl-1 H-pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl)phenylamino]-1 ,3,5-triazine with the formula

with

with the exception of the combination of 8% by weight of 2-(1-benzhydryl-1 H-pyrrol-2- yl)-4,6-bis[4-(butoxycarbonyl)phenylamino]-1 ,3,5-triazine with 60% by weight of ethylhexyl methoxycinnamate and 32% by weight of (2-Hydroxy-4-methoxyphenyl)- phenylmethanone (Benzophenone-3), in each case related to the total weight of all UV-absorbing active substances.

2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydroindol-1 - yl)phenylamino]-1 ,3,5-triazine with the formula

with

at least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine.

2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-((2-ethylhexyloxy)carbonyl)phenylamino]-1 ,3,5- triazine with the formula

with

at least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2, 4- dihydroxyphenyl)-1 ,3,5-triazine. Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)

2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(1 H-imidazo[1 ,2-a]pyridin-2-yl)phenylamino]- 1 ,3,5-triazine with the formula

with

at least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine.

2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(1 H-benzo[d]imidazol-2-yl)phenylamino]-1 ,3,5- triazine with the formula

with at least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine.

2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(1 H-pyrazol-1-yl)phenylamino]-1 ,3,5-triazine with the formula

with

2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis[naphthalen-2-ylamino]-1 ,3,5-triazine with the formula

with

2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-((E)-3-ethoxy-3-oxoprop-1 -enyl)phenylamino]- 1 ,3,5-triazine with the formula

with

at least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2, 4- dihydroxyphenyl)-1 ,3,5-triazine.

2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(E)-styrylphenylamino]-1 ,3,5-triazine with the formula

with

The active substances (A) of the general formula (I), in particular, the pyrrolyltriazine derivatives of general formula I, in which A¹ is a radical of general formula (III) and A² is a radical of general formula (V) are as defined above, with R¹⁰ being hydrogen; in which R¹, R², R³, R⁴' R⁵, R⁸, R⁹ and n have the meaning indicated above, can be prepared as indicated in reaction scheme 1 :

Scheme 1

(VIl) (VIM)

(Xl)

(IX)

(IA)

Briefly, the compounds of general formula (VIII) are prepared as described in US patent 5,955,060 and Chakrabarti, J. K. and Tupper, D. E., J. Het. Chem. 1974, 11 (3), 417-421.

The compound of general formula (IX) is obtained by Friedel-Crafts acylation of resorcinol with the compound of general formula (VIII) in the presence of a Lewis acid, in particular aluminium chloride, in an inert solvent such as xylene (mixture of isomers) and at a temperature between 60⁰C and 10O⁰C, in accordance with the process described in US patent 5,955,060.

The sterification of the p-hydroxyl groups that leads the compounds of general formula (Xl) to be obtained is carried out by alkylation of the compounds of general formula (IX) with a compound of general formula (X), with R⁸ being as defined above, and X being a leaving group such as chloro, bromo, tosyl or mesyl, in the presence of a base, such as sodium hydroxide, cesium carbonate, potassium carbonate, sodium tert-butoxide and potassium tert-butoxide, in an appropriate polar solvent such as 2- methoxyethanol, 2-ethoxyethanol, N-methylpyrrolidone, N.N-dimethylformamide and ethanol, at a temperature that ranges between 80⁰C and 120⁰C.

The trialkylated compounds of general formula (IA) are obtained by alkylation of the compound of general formula (Xl) with a compound of general formula (XII), in which R⁹ and X have the meaning as defined above, in the presence of a base, such as potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium tert-butoxide and potassium tert-butoxide, in a polar solvent such as 2- methoxyethanol, 2-ethoxyethanol, N-methylpyrrolidone, N,N-dimethylformamide and ethanol, and at a temperature that ranges between 120⁰C and the boiling temperature of the solvent.

When the R⁸ and R⁹ radicals are the same, the corresponding compound of general formula (IA) is obtained directly from the compound of general formula (IX).

The compounds of general formula (I) in which R¹⁰ is -SO₃M, with M as defined above, can be obtained, for example, by following the procedures described in US patent 6,090,370, in particular column 5, line 59-column 6, line B.

The compounds of general formula (I), in which a -SO₃M group has been inserted into an alkylic chain, and with M as defined above, can be obtained, for example, by following the procedures described in Lewin, G. et al., J. Nat. Prod., 58 (1995) 12,

1840-1847.

The compounds of general formula (I), in which a - N(R¹⁵J₃ ⁺ group has been inserted into an alkylic chain, and with R¹⁵ as defined above, can be obtained, for example, by following the procedures described in Sharma, M. L. et al., J. Indian Chem. Soα, 74(1997)4, 343-344.

According to another embodiment of the process, the triazine derivatives of general formula (I) in which A¹ and A² are the same as each other and correspond to a radical of general formula (IB):

and where R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and n have the meaning stated above, can be prepared as shown in reaction scheme 2.

Scheme 2

Briefly, the compound of general formula (VIII), prepared as defined above, reacts with at least 2 equivalents of aniline of general formula (XIII)₁ with R⁶ and R⁷ being as defined above, in the presence of a base such as N.N-diisopropylethylamine, potassium carbonate, sodium carbonate, caesium carbonate, sodium hydroxide or potassium hydroxide in a solvent such as dioxane, toluene, xylene (mixture of isomers), N,N-dimethylformamide, N-methylpyrrolidone or acetone, at a temperature that ranges between 0⁰C and the boiling temperature of the solvent, preferably between ambient temperature and the boiling temperature of the solvent, and more preferably between 50°C and the boiling temperature of the solvent.

The combination of active substances (A) and (B) according to the present invention has preferably an UV-A/UV-B protection ratio in the range of 0,1 to 1 , more preferably 0,2 to 1 , most preferably 0,3 to 1.

The UV-A/UV-B protection ratio defines the performance of a sunscreen in the UV-A radiation range (320-400nm) in relation to its performance in the UV-B radiation range (290-320nm). It is calculated as the ratio between the areas defined by the UV- A and UV-B radiation absorption capacity. Both areas are normalized to the range of wavelength involved. A ratio value of 1 indicates that a sunscreen absorbs comparably in UV-A and UV-B radiation range, but is silent about the absolute absorption capacity of a product. If a sunscreen absorbs poorly in the UV-B range, the UV-A/UV-B ratio may be even higher than 1. Preferred UV-A/UV-B protection ratios for the inventive combination are in the range as mentioned before.

For the performance and/or the suitability of sunscreens it is convenient to know also their absolute absorption capacity.

The inventive combination absorbs preferably at least 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90 or 95% of the total UV-A and UV-B radiation (290 to 400 nm), more preferably at least 50%, even more preferably at least 70%, most preferably at least 85% of the total UV-A and UV-B radiation range (290 to 400 nm).

The term "absorption of the total UV-A and UV-B radiation" according to the present invention is a measure for the absorption capacity of the inventive combination and refers to the overall absorption in a radiation range from 290 to 400 nm. The total absorption capacity is given by the area under the absorption curve (AUC) in the UV radiation range from 290 to 400 nm.

Preferably, the inventive combination absorbs not only at least 10, 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90 or 95% of the total UV-A radiation (320 to 400 nm), but also at least 10, 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90 or 95% of the total UV-B radiation (290 to 320 nm). In case that the inventive combination absorbs in both the UV-A and UV-B radiation range, the absorption of the total UV-A and UV-B radiation must not exceed 100%. For example, if the inventive combination absorbs 20% in the UV-A radiation range, the maximal absorption in the UV-B radiation range may be 80%.

Another aspect of the present invention is a pharmaceutical composition comprising the combination of UV-absorbing substances (A) and (B) as defined above, and optionally at least one pharmacologically acceptable auxiliary agent, as well as to a cosmetical composition comprising the combination of UV-absorbing substances (A) and (B) as defined above and optionally at least one cosmetical vehicle.

According to the present invention, the inventive pharmaceutical composition comprising the combination of UV-absorbing substances (A) and (B) as defined above may contain at least one further pharmaceutically active substance. Such further pharmaceutically active substance is preferably suitable for the prophylaxis or the treatment of diseases caused by and/or associated with exposure to UV radiation to the skin of mammals, preferably human beings, so that a better therapeutical effect is achieved.

The amount of the UV-absorbing active substance (A) and of the UV-absorbing active substance (B) for the inventive pharmaceutical or cosmetical composition is preferably in each case in the range of 0.01% to 30% per weight, more preferably 0.01% to 20% per weight, most preferably 0.1% to 15% per weight, with respect to the total weight of the composition.

For the inventive pharmaceutical or cosmetical composition the inventive combination may be preferably used in micronized form, wherein the size of the particles is preferably in the range of 0.01 to 4 μm, more preferably in the range of 0.05 to 2 μm, most preferably in the range of 0,05 to 1 μm.

The following auxiliary agents mentioned below can independent of each other be present in either the inventive pharmaceutical or the inventive cosmetical composition: gelling agents, oils, waxes, thickening agents, hydrophilic or hydrophobic polymers, emulsifying agents, emollients, fatty acids, organic solvents, antioxidants, stabilizers, sequestering agents, acidifying or basifying agents, emulsifiers, emollients, surfactants, film formers, biological additives to enhance performance and/or consumer appeal such as amino acids, proteins, vanilla, aloe extract or bioflavinoids, buffering agents, chelating agents such as ethylenediaminetetra-acetic acid (EDTA) or oxalic acid, colorants, dyes, propellants, antifoaming agents, wetting agents, vitamins, emulsion stabilizers, pH adjusters, thickening agents, fragrances, preservatives, opacifying agents, water and/or alcohols. The aforementioned auxiliary agents for the inventive compositions are used in the usual amounts known by those skilled in the art.

As oils for the inventive compositions oils from animal or vegetable sources or synthetic are preferably used. Particularly preferred are oils selected from the group comprising liquid petrolatum, liquid paraffin, volatile and non-volatile silicone oils, isoparaffins, polyalphaolefins, fluorated and perfluorated oils.

As stabilizers for the inventive compositions preferably non-ionic, anionic, cationic and amphiphilic tensides can be used, which are preferably selected from the group comprising polyethylenglycol (PEG) and derivatives thereof, tweens, tritons, spans, polygycerines, polyalkyl glycerides, alkyl sulfonates, aryl sulfonates, alkyl phosphates, derivatives of alkyl-betaine and phosphatidylglycerole.

Emulsifiers are preferably used in certain formulations of the inventive compositions in amounts effective to provide uniform blending of ingredients of the composition. Useful emulsifiers include anionics such as fatty acid soaps, e.g., potassium stearate, sodium stearate, ammonium stearate, and triethanolamine stearate; polyol fatty acid monoesters containing fatty acid soaps, e.g., glycerol monostearate containing either potassium or sodium salt; sulfuric esters (sodium salts), e.g., sodium lauryl 5 sulfate, and sodium acetyl sulfate; and polyol fatty acid monoesters containing sulfuric esters, e.g., glyceryl monostearate containing sodium lauryl surfate; (ii) cationics chloride such as N(stearoyl colamino formylmethyl) pyridium; N-soya-N-ethyl morpholinium ethosulfate; alkyl dimethyl benzyl ammonium chloride; diisobutylphenoxytheoxyethyl dimethyl benzyl ammonium chloride; and acetyl pyridium chloride; and (iii) nonionics such as polyoxyethylene fatty alcohol ethers, e.g., monostearate; polyoxyethylene lauryl alcohol; polyoxypropylene fatty alcohol ethers, e.g., propoxylated oleyl alcohol; polyoxyethylene fatty acid esters, e.g., polyoxyethylene stearate; polyoxyethylene sorbitan fatty acid esters, e.g., polyoxyethylene sorbitan monostearate; sorbitan fatty acid esters, e.g., sorbitan; polyoxyethylene glycol fatty acid esters, e.g., polyoxyethylene glycol monostearate; and polyol fatty acid esters, e.g., glyceryl monostearate and propylene glycol monostearate; and ethoxylated lanolin derivatives, e.g., ethoxylated lanolins, ethoxylated lanolin alcohols and/or ethoxylated cholesterol.

Emollients may be used in the formulations of the inventive compositions in such amounts to prevent or relieve dryness. Useful emollients include, without limitation hydrocarbon oils and waxes; silicone oils; triglyceride esters; acetoglyceride esters; ethoxylated glyceride; alkyl esters; alkenyl esters; fatty acids; fatty alcohols; fatty alcohol ethers; etheresters; lanolin and derivatives; polyhydric alcohols (polyols) and polyether derivatives; polyhydric alcohol (polyol) esters; wax esters; beeswax derivatives; vegetable waxes; phospholipids; sterols; and/or amides.

Surfactants can be used in certain formulations of the inventive compositions. Suitable surfactants are for example those surfactants generally grouped as cleansing agents, emulsifying agents, foam boosters, hydrotropes, solubilizing agents, suspending agents and non-surfactants, which facilitate the dispersion of solids in liquids.

Suitable film formers which are preferably used in the formulations of the inventive compositions should keep the composition smooth and even and are preferably, without limitation, at least one substance selected from the group comprising acrylamide/sodium acrylate copolymer; ammonium acrylates copolymer; Balsam Peru; cellulose gum; ethylene/maleic anhydride copolymer; hydroxyethylcellulose; hydroxypropylcellulose; polyacrylamide; polyethylene; polyvinyl alcohol; pvm/MA copolymer (vinyl methylether/maleic anhydride copolymer); PVP (polyvinylpyrrolidone); maleic anhydride polymer, vinylpyrrolidon/hexadecene copolymer; acryliclacrylate copolymer and the like. pH adjusters may also be used in certain formulations of the inventive compositions. These pH adjusters preferably comprise, but are not limited to ammonium hydroxide, triethanolamine or citric acid.

Thickening agents used for the formulations of the inventive compositions preferably are, but are not limited to candelilla, carnauba, and microcrystalline waxes, crosslinked acrylic-acid polymers, carbomer, methylhydroxyethylcellulose, hydroxypropylmethylcellulose or hydroxyethylcellulose. and polyethylene thickeners.

Examples of preferred organic solvents for the inventive compositions include lower aliphatic alcohols and polyols.

Suitable antioxidants suitable for the inventive compositions are preferably selected from the group comprising ascorbic acid (vitamin C), sodium-L-ascorbate, calcium-L- ascorbate, ascorbyl palmitate, butylhydroxyanisole, butylhydroxytoluene, calcium- disodium-EDTA, isoascorbic acid, lecitine, lactic acid, polyphosphate, tocopherol (vitamin E), like α-tocopherol, γ-tocopherol, δ-tocopherol, propylgallate, octylgallate, dodecylgallate, sodium-isoascorbate, citric acid, sodium citrate, potassium citrate and tin-ll-chloride.

Gelling agents, which are preferably used in the formulations of the inventive compositions, can be natural or synthetic polymers. Natural polymers are preferably selected from the group comprising Agar-Agar, alginate, pectin, carbomer, carrageenan, casein, dextrine, gelatine, arabic gum, keratine, locust bean gum, xanthan gum and the like. Preferred synthetic polymers which can be used in the formulations of the inventive compositions are selected from the group comprising acylic acid polymers, polyacryl amides and alkylene oxide polymers.

For the inventive cosmetical composition marketed in Europe the respective components shall be used in amounts which are in compliance with the Council Directives 76/768/EEC and Commission Directive 95/17/EC on the approximation of the laws of the Member States relating to cosmetic products. The inventive pharmaceutical or cosmetical composition is preferably adapted at least for a once a day, twice or three, four or five times a day, preferably for twice a day application.

For the application, preferably topical application, the inventive pharmaceutical or cosmetical composition may be formulated in liquid or in semi-solid form, preferably as liquid, fluid, foam, cream, gel, paste, balsam, spray, ointment, lotion, conditioner, tonic, milk, mousse, emulsion, serum, oil, stick, shampoo, jelly, suspension, dispersion, lacquer, paint, elixir, drop or aerosol.

Preferably the inventive pharmaceutical or cosmetical compositions are suitable for protecting the skin of UV radiation, either in the range of UV-A or UV-B or the whole UV-A and UV-B range.

A measure for the UV-protecting property of an UV-absorbing composition is the "sun protection factor" (SPF). The SPF of an UV-absorbing composition determined in vivo is a universal indicator of the efficacy against sunburn - the higher the SPF, the more effective is the protection against UV radiation. The level of sun protection has traditionally been estimated using the sun protection factor or SPF test, which utilises the erythemal response of the skin to ultraviolet (UV) radiation. The SPF is a ratio calculated from the energies required to induce a minimum erythemal response with and without sun product applied to the skin of human volunteers, using ultraviolet radiation usually from an artificial source. The determination of the SPF is described in detail in the following references, which are herewith introduced as reference and shall form part of the disclosure or the present application: Diffey BL et., "In vitro assessment of the broad spectrum ultraviolet protection of sunscreen products", J. Am. Acad. Dermatol., 2000, 43(6), 1024-1035 respectively Diffey B. "A method for broad-spectrum classification on sunscreens", lnt J Cosmet Sci. 1994; 16:47-52.

Preferably, the SPF of the inventive pharmaceutical or cosmetical compositions is at least 8, more preferably at least 10, even more preferably at least 15 and most preferably at least 20. The UV-A/UV-B ration of the inventive pharmaceutical or cosmetical compositions can be also determined according to the methods disclosed in the before mentioned publications of Diffey B. respectively Diffey BL.

The inventive pharmaceutical or cosmetical compositions are particularly suitable for keeping scalp, skin, hair and/or nails in good conditions or for moisturizing the skin, treating dry skin successfully and/or against skin ageing and/or photoageing.

Moreover, the inventive combinations are preferably suitable for the prophylaxis of diseases caused by and/or associated with exposure to ultraviolet radiation on the skin, preferably the lips, the face and/or the body of mammals.

Human exposure to solar ultraviolet radiation has important public health implications. Evidence of harm associated with overexposure to UV radiation has been demonstrated in many studies (see e.g. Environmental Burden of Disease Series, No. 13, 2006; Solar Ultraviolet Radiation - Global burden of disease from solar ultraviolet radiation, World Health Organization). Skin cancer and malignant melanoma are among the most severe health effects, but a series of other health effects, such as polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, chronic actinic dermatitis or sunburn have been identified.

Skin cancer is an increasingly common condition, in part attributed to increased exposure to ultraviolet radiation. The increased exposure is mainly due to the recent popularity of sun tanning (sun bathing). Lighter-skinned individuals are more vulnerable. In the United States, about one out of every three new cancers arises from skin. The most common types are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) which may be locally disfiguring but unlikely to spread to other parts of the body. The most dangerous type is malignant melanoma, which can be fatal if not treated early, but forms only a small proportion of all skin cancers.

Squamous cell carcinoma is a form of cancer of the carcinoma type that may occur in many different organs, including the skin, mouth, esophagus, lungs, and cervix. It is a malignant tumour of epithelium that shows squamous cell differentiation. Squamous cell carcinomas account for about 20% of non-melanoma skin cancers, (with basal cell carcinomas accounting for about 80%), but are clinically more significant because of their ability to metastasize. Squamous cell carcinoma is usually developed in the epithelial layer of the skin and sometimes in various mucous membranes of the body. This type of cancer can be seen on the skin, lips, inside the mouth, throat or esophagus. This type of cancer is characterized by red, scaly skin that becomes an open sore. One risk factor for squamous cell carcinoma is exposure to sunlight.

Basal cell carcinoma (BCC) is the most common skin cancer. It can be destructive and disfiguring. Risk is increased for individuals with a family history of the disease and a high cumulative exposure to UV light via sunlight or, in the past, carcinogenic chemicals especially arsenic. BCC is much more common in fair skinned individuals with a family history of basal cell cancer and increases in incidence closer to the equator at higher altitude. Most sporadic BCC arise in small numbers on sun- exposed skin of people over age 50, although younger people may also be affected.

Polymorphic light eruption is a common rash that occurs as a result of photosensitivity. Polymorphic light eruption (PMLE) generally occurs in adult females aged 20 to 40, although it sometimes affects children and rarely males. It is more common in places where sun exposure is uncommon, such as Northern Europe, where it is said to affect 10% of women holidaying in the Mediterranean. It can be the first sign of lupus erythematosus, but this is not usually the case. The name 'polymorphic', or 'polymorphous' refers to the fact that the rash can take many forms, although in one individual it usually looks the same every time it appears. The commonest variety is crops of 2-5 mm pink or red raised spots occurring on the arms. Other areas may be involved, particularly the chest and lower legs, but the face is usually spared.

Actinic keratosis is one type of skin cancer, which appears as rough, red or brown, scaly patches on the skin. It is a precancerous condition and develops sometimes into squamous cell cancer. Solar urticaria is the development of hives minutes after exposure to the sun, which resolve in less than 1 hour. Tan skin that has been previously exposed may not react. Solar urticaria is divided into 6 different types depending on the wavelength of light involved.

Xeroderma pigmentosum, or XP, is a genetic disorder of DNA repair in which the body's normal ability to remove damage caused by ultraviolet (UV) light is deficient. This leads to multiple basaliomas and other skin malignancies at a young age. In severe cases, it is necessary to avoid sunlight.

Skin ageing is a normal process of life but one that many individuals do not take gracefully. With increasing age, cellular cohesion is reduced, renewal time is slower and the elastic tissue degenerates resulting in wrinkles and sagging. Degenerative changes in elastic tissue begin at about 30. The rate of age related changes is influenced by heredity, personal hygiene practices, nutrition, general health and history of sun, radiation and chemical exposure. During the ageing process, cellular cohesion is reduced, the renewal time of the cell layer slows, the moisture content is diminished. The elastic tissues is degraded by enzymes. Photoageing is characterised by chronic inflammation, elastosis.

Chronic actinic dermatitis (CAD), sometimes known as photosensitivity dermatitis/actinic reticuloid syndrome (PD/AR), is a condition in which the skin becomes inflamed, particularly in areas that have been exposed to sunlight or artificial light.

A sunburn is a burn to the skin produced by overexposure to ultraviolet (UV) radiation, commonly from the sun's rays. A similar burn can be produced by overexposure to other sources of UV such as from tanning lamps, or occupationally, such as from welding arcs. Exposure of the skin to lesser amounts of UV will often produce a suntan. Usual mild symptoms are red or reddish skin that's hot to the touch, a washed out feeling, and mild dizziness. Sunburn can be life-threatening and is a leading cause of cancer. Thus, a further aspect of the present invention relates to the use of the inventive combination mentioned above for the preparation of a pharmaceutical composition for the prophylaxis of diseases caused by and/or associated with exposure to ultraviolet radiation, preferably the lips, the face and/or the body of mammals, preferably human beings, more preferably polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, chronic actinic dermatitis and/or sunburn.

Another preferred aspect is the use of the inventive combination for the preparation of a pharmaceutical composition for the prophylaxis and/or care against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing chronic actinic dermatitis and/or sunburn.

Another preferred aspect is the use of the inventive combination for the preparation of a cosmetical composition for the prophylaxis and/or care against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing chronic actinic dermatitis and/or sunburn.

Yet, another preferred embodiment of the present invention is the use of the inventive combination for the preparation of a cosmetical composition for protecting the skin preferably the lips, the face and/or the body of a mammal, preferably a human, against ultraviolet radiation, preferably UV-A and/or UV-B radiation.

An additionally preferred embodiment of the present invention is the use of the inventive combination as described above as a photostabilizer combination additive in polymers and/ or as a component in textile fibers. EXAMPLES

In all examples given below the % by weight of the respective components are related to the total weight of the composition.

The inventive formulations according to the examples are prepared by standard techniques known by those skilled in the art.

Example 1

A cream formulation with the composition:

% by weight

A) 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(2-ethylhexyloxy) 3%

-2-hydroxyphenyl]-1 ,3,5-triazine [λ_max = 350-352 nm]

B) 2-hydroxy-4-methoxy benzophenone (Benzophenone-3) [λ_max = 288 nm] 5%

C) stearyl alcohol (Nacol 18-98 (Sasol)) 1.2%

D) PEG-40 stearate (Simulsol M52 (Seppic)) 2.5%

E) cetearyl ethylhexanoate (DUB Liquide 85) 2.5%

F) caprylic/capryc triglyceride (Miglyol 812N (Sasol) 3.0%

G) C-₁₂-1₅ alkyl benzoate (Tegosoft TN (Goldschmidt)) 5.0% H) phenoxyethanol (and) methylparaben (and) ethylparaben

(and) propylparaben (and) isobutylparaben (and) butylparaben (Phenonip (Clariant)) 0.6% I) polyacrylamide (and) Ci₃-₁₄ isoparaffin (and)

Laureth-7 (Sepigel 305 (Seppic)) 2%

J) cellulose gum (Blanose Cellulose Gum 7H3SF (Hercules)) 0.25% K) water ad 100%

is prepared. Example 2

A cream formulation with the composition:

% by weight

A) 2-(1 -benzyl- 1 H-pyrrol-2-yl)-4,6-bis[4-(2-ethylhexyloxy) 3%

-2-hydroxyphenyl]-1 ,3,5-triazine [λ_max = 350-352 nm]

B) ethylhexyl methoxycinnamate (Parsol MCX) [λ_max = 310 nm] 10%

C) butyl methoxydibenzoylmethane

(Parsol 1789, Avobenzone) [A_max = 357 nm] 3%

D) stearyl alcohol (Nacol 18-98 (Sasol)) 1.2%

E) PEG-40 stearate (Simulsol M52 (Seppic)) 2.5%

F) cetearyl ethylhexanoate (DUB Liquide 85) 2.5%

G) caprylic/capryc triglyceride (Miglyol 812N (Sasol)) 3.0% H) Ci₂-₁₅ alkyl benzoate (Tegosoft TN (Goldschmidt)) 5.0% I) phenoxyethanol (and) methylparaben (and) ethylparaben

(and) propylparaben (and) isobutylparaben (and) butylparaben (Phenonip (Clariant)) 0.6% J) polyacrylamide (and) Ci_3-i₄ isoparaffin (and)

Laureth-7 (Sepigel 305 (Seppic)) 2%

K) cellulose gum (Blanose Cellulose Gum 7H3SF (Hercules)) 0.25%

L) water ad 100%

is prepared.

The UV-A/UV-B ratio of the cream formulation is 0.8 ± 0.02, as determined according to the before mentioned publications of Diffey B. respectively Diffey BL. The SPF of the cream formulation is 9.7 ± 1.2, as determined according to said before mentioned publications. Example 3

A cream formulation with the composition:

% by weight

A) 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6- bis(9-oxo-9H-fluoren-3-ylamino)-1 ,3,5-triazine [λ_max = 292 nm] 3%

B) butyl methoxydibenzoylmethane

(Parsol 1789, Avobenzone) [λ_max = 357 nm] 5%

C) stearyl alcohol (Nacol 18-98 (Sasol)) 1.2%

D) PEG-40 stearate (Simulsol M52 (Seppic)) 2.5%

E) cetearyl ethylhexanoate (DUB Liquide 85) 2.5%

F) caprylic/capryc triglyceride (Miglyol 812N (Sasol)) 3.0%

G) Ci₂-₁₅ alkyl benzoate (Tegosoft TN (Goldschmidt)) 5.0%

H) phenoxyethanol (and) methylparaben (and) ethylparaben (and) propylparaben (and) isobutylparaben (and) butylparaben (Phenonip (Clariant)) 0.6% I) polyacrylamide (and) Ci₃-₁₄ isoparaffin (and)

Laureth-7 (Sepigel 305 (Seppic)) 2%

is prepared. Example 4

A cream formulation with the composition:

% by weight

A) 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(9-oxo-9H- 3% fluoren-3-ylamino)-1 ,3,5-triazine [λ_max = 292 nm]

B) Tinosorb M [λ_max = 358 nm] 6%

C) stearyl alcohol (Nacol 18-98 (Sasol)) 1.2%

D) PEG-40 stearate (Simulsol M52 (Seppic)) 2.5%

E) cetearyl ethyl hexanoate (DUB Liquide 85) 2.5%

F) caprylic/capryc triglyceride (Miglyol 812N (Sasol)) 3.0%

G) C-₁₂-₁₅ alkyl benzoate (Tegosoft TN (Goldschmidt)) 5.0%

H) phenoxyethanol (and) methylparaben (and) ethylparaben (and) propylparaben (and) isobutylparaben (and) butylparaben (Phenonip (Clariant)) 0.6% I) polyacrylamide (and) Ci₃_i₄ isoparaffin (and)

Laureth-7 (Sepigel 305 (Seppic)) 2%

is prepared. Example 5

A cream formulation with the composition:

% by weight

A) 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6- bis(9-oxo-9H-fluoren-3-ylamino)-1 ,3,5-triazine [λ_max = 292 nm] 4%

B) drometrizole trisiloxane (Mexoryl XL) [λ_max = 344 nm] 6%

C) stearyl alcohol (Nacol 18-98 (Sasol)) 1.2%

D) PEG-40 stearate (Simulsol M52 (Seppic)) 2.5%

E) cetearyl ethylhexanoate (DUB Liquide 85) 2.5%

F) caprylic/capryc triglyceride (Miglyol 812N (Sasol)) 3.0%

G) Ci2-1₅ alkyl benzoate (Tegosoft TN (Goldschmidt)) 5.0%

H) phenoxyethanol (and) methylparaben (and) ethylparaben (and) propylparaben (and) isobutylparaben (and) butylparaben (Phenonip (Clariant)) 0.6% I) polyacrylamide (and) Ci₃-1₄ isoparaffin (and)

Laureth-7 (Sepigel 305 (Seppic)) 2%

is prepared. Example 6

A cream formulation with the composition:

% by weight

A) 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(2-ethylhexyloxy) 3%

-2-hydroxyphenyl]-1 ,3,5-triazine [λ_max = 350-352 nm]

B) ethylhexyl methoxycinnamate (Parsol MCX) [λ_max = 310 nm] 5%

C) methylene bis-benzotrianolyl tetramethylbutylphenol (and) decylglucoside (and) propylene glycol (and) xanthan gum (Tinosorb M (Ciba)) [λ_maχ = 358 nm] 5%

D) stearyl alcohol (Nacol 18-98 (Sasol)) 1.2%

E) PEG-40 stearate (Simulsol M52 (Seppic)) 2.5%

F) cetearyl ethylhexanoate (DUB Liquide 85) 2.5%

G) caprylic/capryc triglyceride (Miglyol 812N (Sasol)) 3.0% H) Dimethicone (D 200 Fluid 350 CST (Dow Corning)) 0.5% I) phenoxyethanol (and) methylparaben (and) ethylparaben

Laureth-7 (Sepigel 305 (Seppic)) 2% K) cellulose gum (Blanose Cellulose Gum 7H3SF (Hercules)) 0.25% L) water ad 100%

is prepared.

The UV-A/UV-B ratio of the cream formulation is 0.52 ± 0.01 , as determined according to the before mentioned publications of Diffey B. respectively Diffey BL.

The SPF of the cream formulation is 27.9 ± 3.5, as determined according to said before mentioned publications. Example 7

A cream formulation with the composition:

% by weight

A) 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(2-ethylhexyloxy) 3%

-2-hydroxyphenyl]-1 ,3,5-triazine [λ_max = 350-352 nm]

B) ethylhexyl methoxycinnamate (Parsol MCX) [λ_max = 310 nm] 5%

C) stearyl alcohol (Nacol 18-98 (Sasol)) 1.2%

D) PEG-40 stearate (Simulsol M52 (Seppic)) 2.5%

E) cetearyl ethylhexanoate (DUB Liquide 85) 2.5%

F) caprylic/capryc triglyceride (Miglyol 812N (Sasol)) 3.0%

G) Dimethicone (D 200 Fluid 350 CST (Dow Corning) 0.5% H) phenoxyethanol (and) methylparaben (and) ethylparaben

(and) propylparaben (and) isobutylparaben (and) butylparaben (Phenonip (Clariant)) 0.6% I) polyacrylamide (and) Ci_3-i₄ isoparaffin (and)

Laureth-7 (Sepigel 305 (Seppic)) 2% J) cellulose gum (Blanose Cellulose Gum 7H3SF (Hercules)) 0.25% K) water ad 100%

is prepared.

The UV-A/UV-B ratio of the cream formulation is 0.42 ± 0.02, as determined according to the publications of Diffey B. respectively Diffey BL.

The SPF of the cream formulation is 12.1 ± 1.7, as determined according to said before mentioned publications.

Claims

Claims:

1. A combination of at least 2 UV-absorbing active substances (A) and (B), characterized in that

the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (I),

wherein

n= 0, 1 , 2, 3 or 4;

R¹ represents a hydrogen atom; a linear or branched, unsubstituted or at least monosubstituted C-ι-₃ alkyl radical; or a R² R^{3 "}substituted phenyl- radical;

R², R² , R³ and R³ , independent of each other, each represents a hydrogen atom; a halogen atom; a hydroxy (-OH) residue; an unsubstituted or at least monosubstituted Ci_₃ alkyl radical; an unsubstituted or at least monosubstituted -O-Ci-₃ radical; or an unsubstituted or at least monosubstituted aryl radical;

with the condition that if n=0, R² or R³ does not represent an acryl radical, or

R⁴ and R⁵, independent of each other, each represents a hydrogen atom; an unsubstituted or at least monosubstituted Ci_-4 alkyl radical; or an unsubstituted or at least mono-substituted aryl radical;

A¹ represents a radical of general formula (II), (III) or (IV)

A² represents a radical of general formula (II) or (V)

wherein

R⁶ represents a hydrogen atom; a linear or branched, unsubstituted or at least monosubstituted Ci_-6 alkyl radical; or a hydroxy (-OH) residue;

R⁷ represents a hydrogen atom; an unsubstituted or at least monosubstituted, saturated or unsaturated, C_3-6 cycloalkyl radical; an unsubstituted or at least monosubstituted, saturated or unsaturated C₅-1₀ cycloalkyl radical, which contains 1 , 2 or 3 heteroatom(s) as ring member(s) independently selected from the group consisting of O, N and S; an unsubstituted or at least monosubstituted aryl radical; an unsubstituted or at least monosubstituted Cs- ₁₀ heteroaryl radical which contains 1 , 2 or 3 heteroatom(s) as ring member(s) independently selected from the group consisting of O, N and S; a -C(=O)- OR¹¹ radical; a -C(=O)-NR¹²R¹³ radical; an unsubstituted or at least monosubstituted -0-C-_M8 radical; an unsubstituted or at least monosubstituted -O-phenyl or -O-naphtyl radical; an unsubstituted or at least monosubstituted - COR¹⁴ radical; a linear or branched, saturated or unsaturated, Ci.-iβ aliphatic radical, which is unsubstituted or at least mono-substituted with at least one hydroxy (-OH) residue, a SO₃M moiety, a -N(R¹⁵)₃ ⁺ moiety or a radical of general formula (Vl)

(Vl) wherein

m = O or 1 ;

P = O, 1 , 2, 3 or 4;

R¹⁶, R¹⁷, R¹⁸, R¹⁹ and R²⁰, independent of each other, each represents an unsubstituted or at least mono-substituted Ci-₆ alkyl radical; an unsubstituted or at least mono-substituted -0-Ci_-6 radical; an unsubstituted or at least monosubstituted aryl radical; or an -0-Si(R²¹ )₃ radical;

R²¹ represents an unsubstituted or at least mono-substituted Ci-6 alkyl radical; an -O-Ci_-6 radical; an unsubstituted or at least mono-substituted aryl radical;

R¹¹, R¹² and R¹³, independent of each other, each represents a hydrogen atom; a linear or branched, unsubstituted or at least monosubstituted CM_S alkyl radical; an unsubstituted or at least mono-substituted C3-6 cycloalkyl radical;

or

R¹⁵ represents an unsubstituted or at least mono-substituted CMS alkyl radical;

M represents H, Na⁺ or K⁺;

R⁶ and R⁷ form together with the phenyl ring an unsubstituted or at least mono-substituted 9 to 15-membered polycyclic ring system;

or

R⁶ and R¹⁴ form together with the phenyl ring an unsubstituted or at least mono-substituted 9 to 15-membered polycyclic ring system;

R⁸ and R⁹, independent of each other, each represents a hydrogen atom; an unsubstituted or at least monosubstituted -C(=O)-C-_M8 radical; a linear or branched, saturated or unsaturated C_1-Ie aliphatic radical, which is unsubstituted or at least mono-substituted with at least one hydroxy (-OH) residue, a -SO₃M moiety, a -N(R¹⁵)₃ ⁺ moiety or a radical of general formula (Vl) as defined above; R¹⁰ represents a hydrogen atom; or a -SO₃M moiety with M representing H, Na⁺ or K⁺;

which active substance (A) has its absorption maximum λ_max(A) either in the range of UV-A or UV-B radiation

and

is combined with at least one UV-absorbing active substance (B), which has its absorption maximum λ_max(B) either in the range of UV-A or UV-B radiation, preferably with the proviso that λ_max(B) of active substance (B) does not lie in the same UV radiation range wherein the λ_maX(A) of active substance (A) lies, wherein the ratio of the molar extinction coefficient at λ_max [ελm_ax (A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at λ_max [ελ_max _(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 ;

with the exception of the combination of 37,5% by weight of 2-(1-benzyl-1 H- pyrrol-2-yl)-4,6-bis(9-oxo-9H-fluoren-3-ylamino)-1 ,3,5-triazine with 62,5% by weight of ethylhexyl methoxycinnamate in each case related to the total weight of both UV-absorbing active substances,

with the exception of the combination of 60.5 - 67.6% by weight of 2-(1-benzyl- 1 H-pyrrol-2-yl)-4,6-bis[4-(imidazo[1 ,2-a]pyridin-2-yl)phenylamino]-1 ,3,5-triazine with 32.4 - 39.5% by weight of titanium dioxide, in each case related to the total weight of all UV-absorbing active substances,

with the exception of the combination of 8% by weight of 2-(1-benzhydryl-1 H- pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl)phenylamino]-1 ,3,5-triazine with 60% by weight of ethylhexyl methoxycinnamate and 32% by weight of (2-Hydroxy-4- methoxyphenyl)-phenylmethanone (Benzophenone-3), in each case related to the total weight of all UV-absorbing active substances,

with the exception of the combination of 21 % by weight of 2-(1 -benzyl-1 H- pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl)phenylamino]-1 ,3,5-triazine with 79% by weight of ethylhexyl methoxycinnamate, in each case related to the total weight of both UV-absorbing active substances,

with the exception of the combination of 13.4% by weight of 2-(1 -benzyl-1 H- pyrrol-2-yl)-4,6-bis(4-benzoylphenylamino)-1 ,3,5-triazine with 80% by weight of ethylhexyl methoxycinnamate and 6.6% by weight of (2-Hydroxy-4- methoxyphenyl)-phenylmethanone (Benzophenone-3), in each case related to the total weight of all UV-absorbing active substances,

with the exception of the combination of 52.6 - 56.2% by weight of 2-(1-benzyl- 1 H-pyrrol-2-yl)-4,6-bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-1 ,3,5-triazine/6,6'- (6-(1 -benzyl-1 H-pyrrol-2-yl)-1 ,3,5-triazine-2,4-diyl)bis(3-(2- ethylhexyloxy)phenol) with 43.8 - 47.7% by weight of titanium dioxide, in each case related to the total weight of all UV-absorbing active substances,

and

with the exception of the combination of 51.3% by weight of 2-(1 -benzyl-1 H- pyrrol-2-yl)-4,6-bis(biphenyl-4-ylamino)-1 ,3,5-triazine with 30.7% by weight of ethylhexyl methoxycinnamate, 10.3% per weight of (2-Hydroxy-4- methoxyphenyl)-phenylmethanone (Benzophenone-3) and 7.7% by weight of butyl methoxydibenzoylmethane (Avobenzone), in each case related to the total weight of all UV-absorbing active substances.

2. A combination according to claim 1 , characterized in that the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of general formula (I) according to claim 1 , wherein

A¹ and A², independent of each other, each represents a radical a radical of general formula (II) or (V)

wherein R⁶, R⁷, R⁸ and R⁹ have the meaning according to claim 1 ;

which active substance (A) has its absorption maximum λ_max(_A) in the range of either UV-A or UV-B radiation

and

is combined with at least one UV-absorbing active substance (B) as defined in claim 1 , wherein the ratio of the molar extinction coefficient at λ_max [εxm_ax (A)] of the UV-absorbing active substance (A) to the molar extinction coefficient at λmax [ελmax(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1.

3. A combination according to claim 1 or 2, characterized in that the UV- absorbing active substance (A) is at least one pyrrolyltriazine compound of general formula (IA),

wherein n = 0, 1,2, 3 or 4 and

R¹, R^, R j3^J, D R4⁴, D R5⁰, R D8⁰ and R⁹ have the meaning according to claim 1; and/or is at least one pyrrolyltriazine compound of general formula (IB),

(IB) wherein n = 0, 1 , 2, 3 or 4

and

R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ have the meaning according to claim 1 ;

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt and/or at least one corresponding solvate of the afore mentioned pyrrolyltriazine compounds of general formula (IA) and (IB);

and

is combined with at least one UV-absorbing active substance (B) as defined in claim 1 , wherein the ratio of the molar extinction coefficient at λ_max [ελmax(A)] of the UV-absorbing active substance (A) to the molar extinction coefficient at λm_ax [ελm_aχ(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1.

4. A combination according to anyone of claims 1 to 3, characterized in that the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of general formulae (I), (IA) or (IB),

wherein

and

is combined with at least one UV-absorbing active substance (B) as defined in claim 1 , wherein the ratio of the molar extinction coefficient at λ_max [ε_λmaχ(A)] of the UV-absorbing active substance (A) to the molar extinction coefficient at λmax [ελmax(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1.

5. A combination according to anyone of claims 1 to 4, characterized in that the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of general formulae (I), (IA) or (IB),

wherein

R¹ represents a hydrogen atom; a methyl, ethyl, iso-propyl, n-propyl, benzyl or phenyl radical which is unsubstituted or at least mono-substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of F, Cl, Br, I; methyl, ethyl, iso-propyl, n-propyl, iso-butyl, n-butyl, tert-butyl; -0-CH₃, - O-C₂H₅, -O-CH₂-CH2-CH₃ and phenyl; or a phenyl radical which is in each case substituted with 1 or 2 substituent(s) independently selected from the group consisting of H; methyl, ethyl, iso-propyl, n-propyl and phenyl;

or

R² and R³ form together with the phenyl ring a naphthalene ring which is unsubstituted or at least mono-substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of F, Cl, Br, I; methyl, ethyl, iso-propyl, n-propyl, iso-butyl, n-butyl, tert-butyl; -O-CH₃, -0-C₂H₅, -O-CH2- CH₂-CH₃ and phenyl;

R⁷ represents a a hydrogen atom; -OH; methyl, ethyl, iso-propyl, n-propyl, tert- butyl, n-butyl, iso-butyl, phenyl, benzyl, cyclohexyl, -O-phenyl, biphenyl, - C(=O)-OR¹¹; -C(=O)-NR¹²R¹³; or a radical of general formula (Vl)

(Vl)

wherein

m = 0 or 1 ; p = 0, 1 , 2, 3 or 4;

R¹⁶, R¹⁷, R¹⁸, R¹⁹ and R²⁰, independent of each other, each represents methyl, ethyl, iso-propyl, n-propyl, butyl; -0-CH₃, -0-C₂H₅, -0-CH₂-CH₂-CH₃; or phenyl;

R¹¹, R¹² and R¹³, independent of each other, each represents methyl, ethyl, iso-propyl, n-propyl, tert-butyl, n-butyl, iso-butyl, pentyl, hexyl or 2-ethylhexyl;

and is combined with at least one UV-absorbing active substance (B) as defined in claim 1 , wherein the ratio of the molar extinction coefficient at λ_max [ελmax(A)] of the UV-absorbing active substance (A) to the molar extinction coefficient at λm_ax [ελmax(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1.

6. A combination according to anyone of claims 1 to 5, characterized in that the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound selected from the group consisting of

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4-dihydroxyphenyl)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]- 1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl) phenylamino]-1 ,3,5- triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(biphenyl-4-ylamino)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(4-benzoylphenylamino)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(9-oxo-9H-fluoren-3-ylamino)-1 ,3,5- triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(imidazo[1 ,2-a]pyridin-2- yl)phenylamino]-1 ,3,5-triazine,

- 2-(1-benzhydryl-1 H-pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl)phenylamino]- 1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(6,6-dimethyl-4-oxo-4,5,6,7- tetrahydroindol-1 -yl)phenylamino]-1 ,3,5-triazine

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-((2- ethylhexyloxy)carbonyl)phenylamino]-1 ,3,5-triazine

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-1 H-imidazo[1 ,2-a]pyridin-2- yl)phenylamino]-1 ,3,5-triazine

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(1 H-benzo[d]imidazol-2- yl)phenylamino]-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(1 H-pyrazol-1 -yl)phenylamino]-1 ,3,5- triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[naphthalen-2-ylamino]-1 ,3,5-triazine, - 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-((E)-3-ethoxy-3-oxoprop-1 - enyl)phenylamino]-1 ,3,5-triazine and

and

is combined with at least one UV-absorbing active substance (B) as defined in claim 1 , wherein the ratio of the molar extinction coefficient at λ_max [ελm_ax(A)] of the UV-absorbing active substance (A) to the molar extinction coefficient at λ_max [ελm_ax(_B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1.

7. A combination according to anyone of claims 1 to 6, characterized in that the UV-absorbing active substance (B) has its absorption maximum λ_max(_B) in the range of 290 to 400 nm.

8. A combination according to anyone of claims 1 to 7, characterized in that λ_maχ_(B) of active substance (B) does not lie in the same UV radiation range wherein the λ_maX(A) of active substance (A) lies.

9. A combination according to anyone of claims 1 to 8, characterized in that the UV-absorbing active substance (B) is at least one organic and/or at least one inorganic compound.

10. A combination according to anyone of claims 1 to 9, characterized in that the UV-absorbing active substance (B) is at least one compound selected from the group comprising substituted acrylic acid derivatives, allantoin derivatives, aminobenzoic acid derivatives, aminobenzamides derivatives, anthranilic acid derivatives, benzalmalonic acid derivatives, benzimidazole derivatives, benzoic acid derivatives, benzophenone derivatives, benzothiazole derivatives, benzotriazole derivatives, benzoxazole derivatives, camphor derivatives, cinnamic acid derivatives, coumarinic acid derivatives, curcumin derivatives, dianisoylmethane derivatives, dibenzalazine derivatives, dibenzoylmethane derivatives, dioxane derivatives, fungi extract, ferulic acid derivatives, furane derivatives, glutamic acid derivatives, imidazoline derivatives, metal oxides, metal dioxides, nicotinic acid derivatives, nitrobenzamides derivatives, nitrobenzoic acid derivatives, nucleic acid derivatives, p-aminobenzoic acid (PABA) derivatives, plant extracts, propenoate derivatives, pyrimidine derivatives, salicylic acid derivatives, tetrazole derivatives, triazine derivatives, tributamine derivatives, urocanic acid derivatives and vitamin B₆ derivatives;

which UV-absorbing active substance (B) has its absorption maximum λ_max(B) in the range of 290 to 400 nm;

with the proviso that if the active substance (B) is at least one triazine derivative, this active substance (B) has to be different from a compound, which falls under the definition of compounds of general formulae (I), (IA) and (IB) according to claims 1 to 6.

11. A combination according to anyone of claims 1 to 10, characterized in that the UV-absorbing active substance (B) is at least one compound of general formula (AA)

(AA)

wherein

T¹ and T², independent of each other, each represents a Ci_-8 alkyl radical which can be unsubstituted or at least mono-substituted with radicals independently selected from the group consisting of C-M alkyl, 0₅.₁₂ cycloalkyl and aryl;

and/or

at least one compound of general formula (AB)

(AB)

wherein

T³ represents a -(CONH)_s-phenyl moiety, in which s is 0 or 1 and the phenyl group is unsubstituted or at least mono-substituted with radicals independently selected from the group consisting of -OH, Ci_-I8 alkyl and -0-Ci_-8 alkyl, or a - C(=O)-OT^3' moiety, in which T^3' is a Ci_-18 alkyl radical;

T⁴ represents a hydrogen atom or a Ci_-4 alkyl radical; and T⁵ represents -OH or a -0-Ci_-4 alkyl radical;

and/or

at least one compound of general formula (AC)

(AC)

wherein

T⁶, T⁷, T⁸ and T⁹, independent of each other, each represents a Ci_-8 alkyl radical or an -O-Ci-s alkyl radical;

and/or

at least one compound of general formula (AD)

(AD) wherein T¹⁰, T¹¹ and T¹², independent of each other, each represents a radical selected from the group consisting of phenyl, -O-phenyl or pyrrolyl, which is unsubstituted or at least mono-substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of -OH, -CM_S alkyl, -0-C_1-18 alkyl,

alkyl, Cs-S cycloalkyl, a methylidenecamphor group or a - (CH=CH)_n(CO)-OT^10', with T^10' being either C_1-18 alkyl or cinnamyl, and n is O OM ;

and/or

at least one compound of general formula (AE)

wherein

T -14 represents a hydrogen atom or a Ci_-1S alkyl radical;

T r15 represents a Ci_-8 alkyl radical which can be unsubstituted, an at least mono-substituted with a phenyl radical or a radical of general formula (Vl¹)

(Vl¹) wherein

m' = 0 or 1 ; p¹ = 0, 1 , 2, 3 or 4;

R^16', R^17', R^18', R^19' and R^20', independent of each other, each represents an unsubstituted or at least mono-substituted Ci-₆ alkyl radical; an unsubstituted or at least mono-substituted

radical; an unsubstituted or at least mono- substituted aryl radical; or an -O-Si(R²¹ )₃ radical with R²¹ representing an unsubstituted or at least mono-substituted Ci_-6 alkyl radical; an -0-Ci_-6 radical; an unsubstituted or at least mono-substituted aryl radical;

T¹⁶ represents a d-β alkyl radical, which can be unsubstituted or an at least mono-substituted with a phenyl radical;

and/or

at least one compound of general formulae (AF), (AG) and (AH)

(AF)

(AG)

(AH)

wherein

each of the symbols X, independent of each other represents an oxygen or sulfur atom or a group NT¹⁷ , each of the symbols Z, independent of each other represents a nitrogen atom or a CH group, each of the symbols T¹⁷, independent of each other represents an -OH group, a halogen atom, a linear or branched C-i-β alkyl radical optionally containing a silicon atom, or a linear or branched -0-Ci_-8 alkyl radical, each of the numbers r is independent of each other 0, 1 or 2, u represents an integer ranging from 1 to 4 inclusive, y is equal to 0 or 1 , each of the numbers r is independent of each other equal to 0 or 1 , each of the symbols T¹⁷ independently represents a hydrogen atom or a linear or branched C-i-β alkyl radical or benzyl group optionally containing a silicon atom;

(BA) (BB) (BC) (BD)

(BE) (BF)

(BG) (BH)

(Bl) (BJ) (BK)

(BL) (BM) (BN)

(BO)

wherein

each of the symbols T¹⁸, independent of each other represents a halogen atom or a linear or branched Ci_-4 alkyl or -O-Ci_-4 alkyl radical, or -OH; T¹⁹ represents a hydrogen atom or a linear or branched Ci_-4 alkyl radical; W represents a carbon or a nitrogen atom; c = 0, 1 , 2, 3 or 4; d = 0, 1 or 2 and e = 0 or 1 ;

12. A combination according to anyone of claims 1 to 11 , characterized in that the UV-absorbing active substance (B) is at least one compound selected from the group comprising 2-ethylhexyl 2-cyano-3,3'-diphenylacrylate, ethyl 2-cyano- 3,3'-diphenylacrylate, polymer of N-{(2 and 4)[(2-oxoborn-3- ylidene)methyl]benzyl}acrylamide, methyl 4-aminobenzoate, butyl 4- aminobenzoate, 5-methyl-2-(1 -methylethyl)-cyclohexyl 2-aminobenzoate, glyceryl aminobenzoate, 2-ethylhexyl-p-dimethylethyl-aminobenzoate, 4- aminobenzamide, homomethyl-N-acetyl-anthranilic acid, menthyl antrhanilate, 2-(1 H-benzimidazol-2-yl)-4-methoxyphenol, 2,2'-bis(benzimidazole), monosodium salt of 2-2'-bis-(1 ,4-phenylene)1 H-benzimidazole-4,6-disulphonic acid, 2-phenylbenzimidazole-5-sulphonic acid, δ.δ'.β.β'-tetramethyl^^'- bis(benzimidazole), 5,5^t-dimethyl-2,2'-bis(benzimidazole), 6-methoxy-2,2'- bis(benzimidazole), 1 ,4-phenylenebis(2-benzimidazolyl), 1 ,2- phenylenebis)benzimidazolyl), 1 ,4-phenylenebis(N-2-ethylhexyl-2- benzimidazolyl), 1 ,4-phenylenebis(N-tri-methylsilylmethyl-2-benzimidazolyl), 2- (1 H-benzimidazol-2-yl)benzothiazole, 2-(1 H-benzimidazol-2-yl)benzoxazole, N,N'-dimethyl-2,2'-bis(benzimidazole), phenylbenzimidazole-5-sulfonic acid (Ensulizole) and its salts , 2-2'-bis-(1 ,4-phenylene)1 H-benzimidazole-4,6- disulphonic acid, 3-methylbutyl 4-(dimethylamino)benzoate, 3,3,5- trimethylcyclohexyl 2-hydroxybenzoate (Homosalate), ethyl 4-aminobenzoate, 4,4-((6-(((1 ,1-dimethylethyl)amino)carbonyl)phenyl)amino) 1.S.δ-triazine^Λ- diyl)diimino)bis-,bis-(2-ethyl-hexyl)ester) benzoic acid, 2,4-dihydroxy- benzophenone (Benzophenone-1 ), 2,2'-dihydroxy-4-methoxy-benzophenone (dioxybenzone, Benzophenone-8), 2,2'-dihydroxy-4,4'-dimethoxy- benzophenone, 2,2',4,4^l-tetrahydroxy-benzophenone, 2-hydroxy-4-methoxy-4'- methyl-benzophenone, hydroxymethoxy-benzophenone sulfonic acid, (2- Hydroxy-4-methoxyphenyl)-phenylmethanone (Benzophenone-3), 2-hydroxy- 4-methoxy-benzophenone-5-sulfonic acid (Benzophenone-4) and its salts, 4- phenyl-benzophenone, 2-ethylhexyl-4'-phenyl-benzophenone-2-carboxylate, 2-hydroxy-4-n-octoxy-benzophenone, 4-hydroxy-3-carboxy-benzophenone, 2- hydroxy-4-methoxybenzophenone, 4-(2-β-glucopyranosiloxy)-propoxy-2- hydroxybenzophenone, dihydroxy-dimethoxy-disulfobenzophenone, 2- benzothiazol-2-ylphenol, [2,4'-dihydroxy-3-(2H-benzotriazol-2-yl)-5-(1 ,1 ,3,3- tetramethylbutyl)-2'-n-octoxy-5'-benzoyl]-diphenylmethane, 2,2'-hydroxy-5- methylphenyl-benzotriazole, 2-(2¹-hydroxy-5'-t-octylphenyl)benzotriazole, 2-(2'- hydroxy-5'-methylphenyl)benzotriazole, 2,2'-methylene-bis-6-(2H-benzotriazol- 2-yl)-4-(tetramethyl-butyl)-1 ,1 ,3,3-phenol, 2-benzoxazole-2-yl-4-methylphenol, 2-phenyl-5-methylbenzoxazole, 1 ,4-phenylenebis(2-benzoxazolyl), 1 ,3- phenylenebis(2-benzoxazolyl), 1 ,2-phenylenebis(2-benzoxazolyl), 2-(2- benzofuryl)-benzoxazole, 2-(benzofuryl)-5-methylbenzoxazole, 2-(3-methyl-2- benzofuryl)benzoxazole, 3-(4'-methylbenzylidene)-D,L-camphor, terephthalylidene dicamphor sulphonic acid, 3-benzylidene-D,L-camphor, 4- benzylidene-D,L-camphor, di-tert-butyl hydroxybenzylidene camphor, benzylidene camphor sulphonic acid, camphor benzalkonium methosulfate, polyacrylamido-methyl benzylidene camphor, ethylhexyl methoxycinnamate, diethanolamine p-methoxy cinnamate, isopropyl-p-acetamido cinnamate, octyl cinnamate, ethyl-4-isopropylcinnamate, methyl-2,5-diisopropyl cinnamate, ethyl-2,4-diisopropylcinnamate, methyl-2,4-diisopropylcinnamate, propyl-p- methoxycinnamate, isopropyl-p-methoxycinnamate, diisopropylcinnamate esters, isoamyl-p-methoxycinnamate, cyclohexyl-p-methoxycinnamate, ethyl- α-cyano-β-phenylcinnamate, 2-ethylhexyl-α-cyano-β-phenylcinnamate, glycerin-mono^-ethyl-hexanoyl-diparamethoxycinnamate, glyceryl octanoate- di-p-methoxycinnamate, DEA-methoxycinnamate, methyl-bis(trimethyl- siloxy)silyl-isopentyl-trimethoxycinnamate, ethyl-α-cyano-3,5-dimethoxy-4- hydroxy cinnamate, ethyl-α-acetyl-3,5-dimethoxy-4-hydroxy cinnamate, iso- propyl-α-acetyl-3,5-dimethoxy-4-hydroxy cinnamate, iso-amyl-α-acetyl-3,5- dimethoxy-4-hydroxy cinnamate, 2-ethylhexyl-α-acetyl-3,5-dimethoxy-4- hydroxy cinnamate, ethyl-α-cyano-3-methoxy-4-hydroxy cinnamate, ethyl-α- acetyl-3-methoxy-4-hydroxy cinnamate, iso-propyl-α-acetyl-3-methoxy-4- hydroxy cinnamate, iso-amyl-α-acetyl-3-methoxy-4-hydroxy cinnamate, 2- ethylhexyl-α-acetyl-3-methoxy-4-hydroxy cinnamate, 7-ethylamino-4- methylcoumarin, 7,8-dihydroxycoumarin, 6,7-dihydroxycoumarin, 7- hydroxycoumarin, 4-methyl-7-hydroxycoumarin, diacetylcurcumin, tetrahydrocurcumin diacetate, dianisoylmethane, dibenzalazine, butyl methoxydibenzoylmethane (Avobenzone), 2-methyldibenzoylmethane, 4- methyldibenzoylmethane, 4-isopropyldibenzoylmethane, 4-tert- butyldibenzoylmethane, 2,4-dimethyldibenzoylmethane, 2,5- dimethyldibenzoylmethane, 4,4¹-diisopropyldibenzoylmethane, 4,4'- dimethoxydibenzoylmethane, 2-methyl-5-isopropyl-4'- methoxydibenzoylmethane, 2-methyl-5-tert-butyl-4'- methoxydibenzoylmethane, 2,4-dimethyl-4'-methoxydibenzoylmethane, 2,6- dimethyM-tert-butyM'-methoxydibenzoylmethane, ferulic acid, dimethicodiethylbenzalmalonate, diethyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, di-(2-ethylhexyl)-3,5-dimethoxy-4-hydroxy benzylidene malonate, diisoamyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, didodecyl-3,5- dimethoxy-4 hydroxy benzylidene malonate, dipalmitoyl-3,5-dimethoxy-4- hydroxy benzylidene malonate, di-isopropyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, diethyl-3-methoxy-4-hydroxy benzylidene malonate, di- (2-ethylhexyl)-3-methoxy-4-hydroxy benzylidene malonate, diisoamyl-3- methoxy-4-hydroxy benzylidene malonate, didodecyl-3-methoxy-4-hydroxy benzylidene malonate, dipalmitoyl-3-methoxy-4-hydroxy benzylidene malonate, di-isopropyl-3-methoxy-4-hydroxy benzylidene malonate, hydrolyzed aspergillus sp. extract ferment, calcium cerium oxide, cerium oxide, iron oxide, manganese oxide, titanium dioxide, zinc oxide, zinc cerium oxide, zirconium oxide, 4-nitrobenzamide, 4-nitrobenzoic acid, p-aminobenzoic acid (PABA), PABA-monoglycerinester, N,N-dipropoxy-PABA-ethylester, N₁N- diethoxy PABA-ethylester, N,N-dimethyl PABA-ethylester, N.N-dimethyl PABA-butylester, PEG-25 PABA, N,N-dimethyl PABA-amylester, N,N-dimethyl PABA-octlylester (2-ethylhexyl 4-(dimethylamino)benzoate, Padimate O), octyl dimethyl PABA, ethyl-dihydroxypropyl-PABA, isoamyl dimethyl PABA (3- methylbutyl 4-(dimethylamino)benzoate, Padimate A), 1-(3,4- dimethoxyphenyl)-4,4-diemthyl-1 ,3-pentanedione, 5-(3,3-Dimethyl-2- norbornyliden)-3-pentane-2-one, 1 -(4-methoxyphenyl)-3-(4-tert- butylphenyl)propane-1 ,3-dione, dipropylene glycol salicylate, 2-ethylhexyl 2- cyano-3,3-diphenyl-2-propenoate (Octocrylene), hydrolyzed soy extract, hydrolyzed linseed extract, sunflower seed extract, grape seed extract, pinus pinaster bark extract, pinus pinaster bud extract, ginseng extract ferment, spirulina platensis powder, phenyl salicylate, p-tert-butylphenyl salicylate, p- octylphenyl salicylate, 2-ethylhexyl salicylate (octyl salicylate), amyl salicylate, menthyl salicylate, homomenthyl salicylate, benzyl salicylate, p-isopropanol- phenyl salicylate, TEA-salicylate, 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2- methyl-3-[1 ,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol (Mexoryl XL), 2-[p-(tert-butylamido)anilino]-4,6-bis[p-(2^I-ethylhexyl-1 '- oxycarbonyl)anilino]-1 ,3,5-triazine (INCI name: Diethylhexyl Butamido Triazone), 2,4,6-tris[4-(2-ethylhexyl-oxycarbonyl)-anilino]-1 ,3,5-triazine (INCI name: Ethylhexyl Triazone), (1 ,3,5)-triazine-2,4-bis((4-2-ethyl-hexyloxy)-2- hydroxy)-phenyl)-6-(4-methoxy-phenyl) (bemotrizinol), octyl triazone (CAS-no. 88122-99-0), urocanic acid, ethyl-urocanic acid, talc, kaolin, calcium carbonate, , bisoctrizole (CAS-no.: 103597-45-1), bornelone (CAS-no.: 2226- 11-1 ), 2-Hydroxy-1 ,4-naphthochinone (Lawsone, CAS-no.: 83-72-7), petrolatum red, phenol sulphonate, sodium 3,4-dimethylphenyl-glyoxylate, 3,3^I-(1 ,4-phenylenedimethylene-bis-(7,7-dimethyl-2-oxobicyclo-[2,2,1]hept-1- yl-methanesufonic acid, α-(2-oxobom-3-ylidene)-toluene-4-sulphonic acid, 2- (2H-benzotriazole-2-yl)-4-methyl-6-[2-methyl-3-[1 ,3,3,3-tetramethyl-1- [(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol (INCI name: drometrizole trisiloxane, DTS), digalloyl trioleate, dimethicone/PEG-15 crosspolymer, ethylhexyl-bis-isopentyl-benzoxazolyl-phenyl melamine and 2-ethylhexyl- dimethoxy-benzylidene-dioxo-imidazolidine propionate;

and/or

a compound of general formula (X)

(X)

wherein

R^1x represents a hydrogen atom; an optionally substituted cycloalkyl radical from 3 to 7 carbon atoms; an aryl radical which is unsubstituted or at least mono-substituted with a group selected from aryl, halogen, an -O-Ci_-6 radical and a Ci-₆ alkyl radical; a -phenyl-Ci-₆ alkyl radical; a linear or branched Ci_-S alkyl radical which is unsubstituted or at least mono-substituted with a moiety selected from -SO₃M, -N(R^4x)₃ ⁺ and a radical of general formula (XX)

(XX) wherein

y = 0 or 1 ; z = 0, 1 , 2, 3 or 4;

_R ^5χ _R ^6x _R ^7x _R ^8χ _{and R} ⁹x j_ncj_epenc|_ent _of _each other, each represents an unsubstituted or at least mono-substituted Ci_-6 alkyl radical; an -0-Ci_-6 radical; an unsubstituted or at least mono-substituted aryl radical and an -OSi(R^10x)₃ radical;

R^1Ox represents a Ci-₆ alkyl radical; an -O-C-ι-₆ radical; or an unsubstituted or at least mono-substituted aryl radical;

M represents a hydrogen atom, Na⁺ or K⁺;

R^4x represents an unsubstituted or at least mono-substituted Ci-₆ alkyl radical;

R^2x and R^3x, independent of each other, each represents a hydrogen atom; an unsubstituted or at least monosubstituted C-M alkyl radical; or an unsubstituted or at least mono-substituted aryl radical;

A^1x represents a radical of general formula (X1 ) or (X2)

A L 2X represents a radical of general formula (X1 ), (X3) or (X4)

R represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted Ci-6 aliphatic radical; or a hydroxy (-OH) residue; R^12x represents a hydrogen atom; a -C(=O)-OR^15x radical; a -C(=O)-NR^16xR^17x radical; an unsubstituted or at least monosubstituted -O-Ci.iβ radical; an unsubstituted or at least monosubstituted -O-phenyl radical; a C₅-₇ cycloalkyl radical; a phenyl or a naphtyl radical; a phenyl or a naphtyl radical which are substituted by 1 or 2 substituents which are independently from one another selected from the group consisting of phenyl, Cl, -O-Ci-β alkyl and Ci-₆ alkyl; a linear or branched, saturated or unsaturated Ci.i₈ aliphatic radical which is unsubstituted or at least mono-substituted with -OH, -phenyl or un moiety of general formula (XX) as defined above;

_R ^i5χ R^16x _and R^17x, independent of each other, each represents a hydrogen atom; a linear or branched, unsubstituted or at least mono-substituted C-i.-iβ alkyl radical;

R^14x represents hydrogen atom; or -SO₃M, with M being H, Na⁺ or K⁺;

R^13x and R^l13x, independent of each other, each represents a hydrogen atom; an unsubstituted or at least monosubstituted C(=O)-Ci-i₈ radical; a linear or branched C_MS alkyl radical, which is unsubstituted or at least mono- substituted with at least one hydroxy (-OH) residue, a SO₃M moiety, a - N(R^4x)₃ ⁺ moiety, wherein M and R^4x have the meaning as defined above, or a radical of general formula (XX) as defined above;

13. A combination according to anyone of claims 1 to 12, characterized in that the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound selected from the group consisting of - 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2₎4-dihydroxyphenyl)-1 ,3,5-triazine,

- 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl) phenylamino]-1 ,3,5- triazine,

- 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(biphenyl-4-ylamino)-1 ,3,5-triazine,

- 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(4-benzoylphenylamino)-1 ,3,5-triazine,

- 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(9-oxo-9H-fluoren-3-ylamino)-1 ,3,5- triazine,

- 2-(1 -benzhydryl-1 H-pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl)phenylamino]- 1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[naphthalen-2-ylamino]-1 ,3,5-triazine,

and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt and/or at least one corresponding solvate thereof; which is combined with

at least one inorganic UV-absorbing active substance (B) selected from the group comprising cerium oxide, iron oxide, manganese oxide, titanium dioxide, zinc oxide, zinc cerium oxide and zirconium oxide;

and/or

- 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(1 -methyl-1 H-pyrazol-5- yl)-1 ,3,5-triazine,

- 2-[2, 4-bis (2-ethylhexyloxy)phenyl]-4-[4-(2-ethylhexyloxy)-2- hydroxyphenyl]-6-(1 -methyl-1 H-pyrazol-5-yl)-1 ,3,5- triazine,

- 2,4-bis(2, 4-dihydroxyphenyl)-6(1 -phenyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine,

- 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(1 -phenyl-1 H-pyrazol-5- yl)-1 ,3,5-triazine,

- 2,4-bis [4-(butoxycarbonyl)phenylamino]-6-(1 -methyl-1 H-pyrazol-5-yl)- 1 ,3,5-triazine,

- 2,4-bis{4-[(2-(ethylhexyloxy)carbonyl]phenylamino}-6-(1 -methyl-1 H- pyrazol-5-yl)-1 ,3,5-triazine,

- 2,4-bis [4-(butoxycarbonyl)phenylamino]-6-(1 -phenyl-1 H-pyrazol-5-yl)- 1 ,3,5-triazine,

- 2,4-bis{4-[(2-ethylhexyloxy)carbonyl]phenylamino}-6-(1 -phenyl-1 H-pyrazol- 5-yl)-1 ,3,5-triazine,

14. A combination according to anyone of claims 1 to 13, characterized in that the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound selected from the group consisting of

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4-dihydroxyphenyl)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(butoxycarbonyl)phenylamino]-1 ,3,5- triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(biphenyl-4-ylamino)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(4-benzoylphenylamino)-1 ,3,5-triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(1 H-pyrazol-1-yl)phenylamino]-1 ,3,5- triazine,

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[naphthalen-2-ylamino]-1 ,3,5-triazine,

- 2-( 1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-((E)-3-ethoxy-3-oxoprop-1- enyl)phenylamino]-1 ,3,5-triazine and

- 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis[4-(E)-styrylphenylamino]-1 ,3,5-triazine; and/or at least one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers in any mixing ratio, or at least one physiologically acceptable salt and/or at least one corresponding solvate thereof;

which is combined with

at least one inorganic UV-absorbing active substance (B) selected from the group comprising cerium oxide, iron oxide, manganese oxide, titanium dioxide, zinc oxide, zinc cerium oxide, zirconium oxide;

and/or

at least one UV-absorbing active substance (B) selected from the group comprising 2, 4-bis(2, 4-dihydroxyphenyl)-6-(1 -methyl-1 H-pyrazol-5-yl)-1 , 3, 5- triazine, 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(1 -methyl- 1 H- pyrazol-5-yl)-1 ,3,5-triazine, 2-[2, 4-bis (2-ethylhexyloxy)phenyl]-4-[4-(2- ethylhexyloxy)-2-hydroxyphenyl]-6-(1-methyl-1 H-pyrazol-5-yl)-1 ,3,5- triazine, 2,4-bis(2, 4-dihydroxyphenyl)-6(1-phenyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine, 2,4- bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(1-phenyl-1 H-pyrazol-5-yl)-1 ,3,5- triazine, 2,4-bis [4-(butoxycarbonyl)phenylamino]-6-(1 -methyl-1 H-pyrazol-5-yl)- 1 ,3,5-triazine, 2,4-bis{4-[(2-(ethylhexyloxy)carbonyl]phenylamino}-6-(1 -methyl- 1 H-pyrazol-5-yl)-1 ,3,5-triazine, 2,4-bis [4-(butoxycarbonyl)phenylamino]-6-(1 - phenyl-1 H-pyrazol-5-yl)-1 ,3,5-triazine, 2,4-bis{4-[(2- ethylhexyloxy)carbonyl]phenylamino}-6-(1 -phenyl-1 H-pyrazol-5-yl)-1 ,3,5- triazine and 2-[(4-butoxycarbonyl)phenylamino]-4,6-bis(1 -methyl-1 H-pyrazol-5- yl)-1 ,3,5-triazine,

.

and

15. A combination according to anyone of claims 1 to 14, characterized in that the combination according to claim 1 to 14 has an UV-A/UV-B protection ratio in the range from 0.1 to 1 , preferably in the range from 0.2 to 1.

16. A combination according to anyone of claims 1 to 14, characterized in that the combination absorbs at least 50% of the total UV radiation in a wavelength range from 290 to 400 nm.

17. A combination according to anyone of claims 1 to 14, characterized in that the combination absorbs at least 20% of the UV radiation in a wavelength range from 290 to 320 nm and/or at least 20% of the UV radiation in a wavelength range from 320 to 400 nm.

18. A pharmaceutical composition comprising a combination according to anyone of claims 1 to 17 and optionally at least one pharmacologically acceptable auxiliary agent.

19. A cosmetical composition comprising a combination according to anyone of claims 1 to 17, and optionally at least one cosmetical vehicle.

20. A pharmaceutical or cosmetical composition according to claim 18 or 19, characterized in that the amount of the UV-absorbing active substance (A) and/or the UV-absorbing active substance (B) is in each case from 0.01 % to 30% per weight, preferably 0.01 % to 20% per weight, with respect to the total weight of the composition.

21. A pharmaceutical or cosmetical composition according to anyone of claims 18 to 20, characterized in that the combination according to claims 1 to 17 is in micronized form.

22. A pharmaceutical or cosmetical composition according to claim 21 , characterized in that the particle size of the combination according to claims 1 to 14 is preferably in the range of 0.05 to 2 μm.

23. A pharmaceutical or cosmetical composition according to anyone of claims 18 to 22, characterized in that the composition is suitable for topical application.

24. A pharmaceutical or cosmetical composition according to anyone of claims 18 to 23, characterized in that the composition is formulated in liquid or in semisolid form.

25. A pharmaceutical or cosmetical composition according to anyone of claims 18 to 24, characterized in that the composition is formulated as liquid, fluid, foam, cream, gel, paste, balsam, spray, ointment, lotion, conditioner, tonic, milk, mousse, emulsion, serum, oil, stick, shampoo, jelly, suspension, dispersion, lacquer, paint, elixir, drop or aerosol.

26. A pharmaceutical or cosmetical composition according to anyone of claims 18 to 25, characterized in that the composition is adapted at least for a once a day application.

27. A cosmetic composition according to anyone of claims 18 to 26, characterized in that the composition is suitable for keeping scalp, skin, hair and/or nails in good conditions.

28. Use of a combination according to anyone of claims 1 to 17 for the preparation of a pharmaceutical composition for the prophylaxis of diseases caused by and/or associated with exposure to ultraviolet radiation, preferably the lips, the face and/or the body of mammals, preferably human beings.

29. Use of a combination according to anyone of claims 1 to 17 for the preparation of a pharmaceutical composition for the prophylaxis and/or care against non- desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing and/or chronic actinic dermatitis.

30. Use of a combination according to anyone of claims 1 to 17 for the preparation of a cosmetical composition for the prophylaxis and/or care against non- desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing and/or chronic actinic dermatitis.

31. Use of a combination according to anyone of claims 1 to 17 for the production of a cosmetical composition for protecting the skin preferably the lips, the face and/or the body of a mammal, preferably a human, against ultraviolet radiation, preferably UV-A and/or UV-B radiation.

32. Use of a combination according to anyone of claims 1 to 17 as a photostabilizer combination additive in polymers.

33. Use of a combination according to anyone of claims 1 to 17 as a component in textile fibers.